

WEBVTT

NOTE duration:"00:53:36.1280000"

NOTE language:en-us

NOTE Confidence: 0.84287412897233

00:00:00.000 --> 00:00:02.947 Actual. Post Ash meeting where a few

NOTE Confidence: 0.84287412897233

00:00:02.947 --> 00:00:05.718 minutes late but will try to finish

NOTE Confidence: 0.84287412897233

00:00:05.718 --> 00:00:08.610 on time because I know all of you

NOTE Confidence: 0.84287412897233

00:00:08.610 --> 00:00:11.274 have other things to go too so it's

NOTE Confidence: 0.84287412897233

00:00:11.361 --> 00:00:13.080 a pleasure to start this series.

NOTE Confidence: 0.84287412897233

00:00:13.080 --> 00:00:15.285 I think there has been a lot of new

NOTE Confidence: 0.84287412897233

00:00:15.285 --> 00:00:17.517 and great development in ash meeting

NOTE Confidence: 0.84287412897233

00:00:17.517 --> 00:00:19.940 and because of their virtual format,

NOTE Confidence: 0.84287412897233

00:00:19.940 --> 00:00:21.445 sometimes it's very difficult to

NOTE Confidence: 0.84287412897233

00:00:21.445 --> 00:00:23.870 catch up with all of those articles.

NOTE Confidence: 0.84287412897233

00:00:23.870 --> 00:00:26.804 So we are going to have six weekly sessions.

NOTE Confidence: 0.84287412897233

00:00:26.810 --> 00:00:29.064 The first one today will be about

NOTE Confidence: 0.84287412897233

00:00:29.064 --> 00:00:30.767 multiple myeloma and we will

NOTE Confidence: 0.84287412897233

00:00:30.767 --> 00:00:32.119 cover the other important.

NOTE Confidence: 0.84287412897233

00:00:32.120 --> 00:00:35.865 Disease elements in the next few sessions.

NOTE Confidence: 0.84287412897233

00:00:35.870 --> 00:00:38.258 So this meeting will be recorded.

NOTE Confidence: 0.828498721122742

00:00:40.300 --> 00:00:42.946 And we will have the recording

NOTE Confidence: 0.828498721122742

00:00:42.946 --> 00:00:44.710 available for subsequent viewing.

NOTE Confidence: 0.828498721122742

00:00:44.710 --> 00:00:46.910 Please remember that this is

NOTE Confidence: 0.828498721122742

00:00:46.910 --> 00:00:49.922 also see me credited so you can

NOTE Confidence: 0.828498721122742

00:00:49.922 --> 00:00:52.463 see it get CME credit for this

NOTE Confidence: 0.828498721122742

00:00:52.463 --> 00:00:55.288 hour and for subsequent meetings.

NOTE Confidence: 0.828498721122742

00:00:55.290 --> 00:00:57.936 So today our talk will be

NOTE Confidence: 0.828498721122742

00:00:57.936 --> 00:00:59.259 about multiple myeloma.

NOTE Confidence: 0.828498721122742

00:00:59.260 --> 00:01:01.906 It's a pleasure to have highly

NOTE Confidence: 0.828498721122742

00:01:01.906 --> 00:01:03.229 distinguished and expert.

NOTE Confidence: 0.828498721122742

00:01:03.230 --> 00:01:05.290 Basically speakers today with

NOTE Confidence: 0.828498721122742

00:01:05.290 --> 00:01:07.350 me from Yale University.

NOTE Confidence: 0.828498721122742

00:01:07.350 --> 00:01:09.582 So we'll start with the Doctor

NOTE Confidence: 0.828498721122742

00:01:09.582 --> 00:01:11.070 with Doctor Natalia Nippori.
NOTE Confidence: 0.828498721122742

00:01:11.070 --> 00:01:13.314 See who's an assistant professor of
NOTE Confidence: 0.828498721122742

00:01:13.314 --> 00:01:15.910 medicine and she's going to talk to
NOTE Confidence: 0.828498721122742

00:01:15.910 --> 00:01:17.968 us about updates in the frontline
NOTE Confidence: 0.828498721122742

00:01:17.968 --> 00:01:19.628 management of multiple myeloma.
NOTE Confidence: 0.828498721122742

00:01:19.630 --> 00:01:22.598 This will be followed by Doctor Terry Parker,
NOTE Confidence: 0.828498721122742

00:01:22.600 --> 00:01:25.204 our assistant Professor of Medicine at Yale,
NOTE Confidence: 0.828498721122742

00:01:25.210 --> 00:01:27.070 who's gonna cover the refractory
NOTE Confidence: 0.828498721122742

00:01:27.070 --> 00:01:28.930 and relapsed multiple myeloma then.
NOTE Confidence: 0.828498721122742

00:01:28.930 --> 00:01:30.046 Doctors know far.
NOTE Confidence: 0.828498721122742

00:01:30.046 --> 00:01:30.790 Power Hour,
NOTE Confidence: 0.828498721122742

00:01:30.790 --> 00:01:32.098 assistant professor of Medicine
NOTE Confidence: 0.828498721122742

00:01:32.098 --> 00:01:34.060 who specializes in car T cell
NOTE Confidence: 0.828498721122742

00:01:34.117 --> 00:01:35.620 therapy and transplantation,
NOTE Confidence: 0.828498721122742

00:01:35.620 --> 00:01:37.846 especially on the My llama front.
NOTE Confidence: 0.828498721122742

00:01:37.850 --> 00:01:38.414 She will.

NOTE Confidence: 0.828498721122742
00:01:38.414 --> 00:01:40.670 Cover those for us and this will go
NOTE Confidence: 0.828498721122742
00:01:40.732 --> 00:01:42.796 for around 40 minutes after that.
NOTE Confidence: 0.828498721122742
00:01:42.800 --> 00:01:44.788 At the end we're gonna have 15
NOTE Confidence: 0.828498721122742
00:01:44.788 --> 00:01:46.359 minutes for questions and answers,
NOTE Confidence: 0.828498721122742
00:01:46.360 --> 00:01:48.376 so if I can ask you to write
NOTE Confidence: 0.828498721122742
00:01:48.376 --> 00:01:49.610 down your questions,
NOTE Confidence: 0.828498721122742
00:01:49.610 --> 00:01:51.494 you can write him throughout the
NOTE Confidence: 0.828498721122742
00:01:51.494 --> 00:01:53.159 session and send them to us.
NOTE Confidence: 0.828498721122742
00:01:53.160 --> 00:01:55.176 And just to make sure we can go
NOTE Confidence: 0.828498721122742
00:01:55.176 --> 00:01:57.016 through all the slides will keep
NOTE Confidence: 0.828498721122742
00:01:57.016 --> 00:01:58.918 their questions and until the end
NOTE Confidence: 0.828498721122742
00:01:58.982 --> 00:02:01.117 we're going to have a panelist who
NOTE Confidence: 0.828498721122742
00:02:01.117 --> 00:02:02.598 is Doctor Sabrina Browning who's
NOTE Confidence: 0.828498721122742
00:02:02.598 --> 00:02:04.272 our instructor with a focus on
NOTE Confidence: 0.828498721122742
00:02:04.272 --> 00:02:05.890 amyloidosis and also multiple myeloma.
NOTE Confidence: 0.828498721122742

00:02:05.890 --> 00:02:07.815 All four speakers will be available at
NOTE Confidence: 0.828498721122742

00:02:07.815 --> 00:02:10.049 the end to take questions from you.
NOTE Confidence: 0.828498721122742

00:02:10.050 --> 00:02:12.192 And we look forward to a great
NOTE Confidence: 0.828498721122742

00:02:12.192 --> 00:02:14.248 presentation so Natalia please stop for us.
NOTE Confidence: 0.828498721122742

00:02:14.250 --> 00:02:14.850 Thank you.
NOTE Confidence: 0.805696725845337

00:02:18.930 --> 00:02:22.000 Thank you very much, Doctor Zaidan. Good
NOTE Confidence: 0.805696725845337

00:02:22.000 --> 00:02:25.059 afternoon and thank you all for joining.
NOTE Confidence: 0.805696725845337

00:02:25.060 --> 00:02:27.838 As mentioned, these are the panelists
NOTE Confidence: 0.805696725845337

00:02:27.838 --> 00:02:30.151 joining the discussion today and
NOTE Confidence: 0.805696725845337

00:02:30.151 --> 00:02:32.467 I will begin by up highlighting
NOTE Confidence: 0.805696725845337

00:02:32.467 --> 00:02:34.260 initial therapy and biology.
NOTE Confidence: 0.805696725845337

00:02:34.260 --> 00:02:35.574 Pathophysiology of myeloma.
NOTE Confidence: 0.805696725845337

00:02:35.574 --> 00:02:37.326 These are my disclosures.
NOTE Confidence: 0.805696725845337

00:02:37.330 --> 00:02:40.102 I would like to begin by highlighting
NOTE Confidence: 0.805696725845337

00:02:40.102 --> 00:02:42.276 the work by Doctor Kardashian
NOTE Confidence: 0.805696725845337

00:02:42.276 --> 00:02:44.988 from NCI who presented the work

NOTE Confidence: 0.805696725845337

00:02:44.988 --> 00:02:47.837 on the treatment of high risk,

NOTE Confidence: 0.805696725845337

00:02:47.840 --> 00:02:49.202 smoldering multiple myeloma.

NOTE Confidence: 0.805696725845337

00:02:49.202 --> 00:02:50.527 With carfilzomib, Lenalidomide,

NOTE Confidence: 0.805696725845337

00:02:50.527 --> 00:02:53.029 and dexamethasone, this was a phase

NOTE Confidence: 0.805696725845337

00:02:53.029 --> 00:02:55.440 two clinical in Carrollton study.

NOTE Confidence: 0.805696725845337

00:02:55.440 --> 00:02:58.198 The primary objective was the study was

NOTE Confidence: 0.805696725845337

00:02:58.198 --> 00:03:01.209 to determine the minimal residual disease.

NOTE Confidence: 0.805696725845337

00:03:01.210 --> 00:03:02.982 Negative complete response rates.

NOTE Confidence: 0.805696725845337

00:03:02.982 --> 00:03:04.754 Another key secondary objectives,

NOTE Confidence: 0.805696725845337

00:03:04.760 --> 00:03:06.532 including progression free survival,

NOTE Confidence: 0.805696725845337

00:03:06.532 --> 00:03:07.418 overall survival,

NOTE Confidence: 0.805696725845337

00:03:07.420 --> 00:03:08.758 duration of MRD.

NOTE Confidence: 0.81944128870964

00:03:08.760 --> 00:03:11.562 Negative state. This is the overall

NOTE Confidence: 0.81944128870964

00:03:11.562 --> 00:03:13.910 study design. This study was

NOTE Confidence: 0.818044066429138

00:03:13.910 --> 00:03:16.772 quite inclusive in that this study

NOTE Confidence: 0.818044066429138

00:03:16.772 --> 00:03:19.667 included all patients with high risk
NOTE Confidence: 0.818044066429138

00:03:19.667 --> 00:03:22.367 definition by any of these criteria,
NOTE Confidence: 0.818044066429138

00:03:22.370 --> 00:03:23.915 including Mayo Clinic,
NOTE Confidence: 0.818044066429138

00:03:23.915 --> 00:03:27.005 but Seamus Spanish high risk criteria
NOTE Confidence: 0.818044066429138

00:03:27.005 --> 00:03:29.681 they've defined by flow cytometry based
NOTE Confidence: 0.818044066429138

00:03:29.681 --> 00:03:32.308 on a barren plasma cell expression
NOTE Confidence: 0.818044066429138

00:03:32.308 --> 00:03:35.542 as well as Raj Kumar along Grennan
NOTE Confidence: 0.818044066429138

00:03:35.542 --> 00:03:37.886 Mateus criteria which include plasma
NOTE Confidence: 0.818044066429138

00:03:37.886 --> 00:03:40.246 cell percentage level of protein.
NOTE Confidence: 0.818044066429138

00:03:40.250 --> 00:03:42.914 Humana paresis as well as cytogenetic
NOTE Confidence: 0.818044066429138

00:03:42.914 --> 00:03:44.690 and imaging abnormalities so
NOTE Confidence: 0.818044066429138

00:03:44.765 --> 00:03:47.633 patients on this study received the
NOTE Confidence: 0.818044066429138

00:03:47.633 --> 00:03:49.545 induction therapy with carfilzomib,
NOTE Confidence: 0.818044066429138

00:03:49.550 --> 00:03:50.981 REVLIMID dexamethasone combination.
NOTE Confidence: 0.818044066429138

00:03:50.981 --> 00:03:53.843 For eight cycles of therapy followed
NOTE Confidence: 0.818044066429138

00:03:53.843 --> 00:03:55.966 by Lenalidomide maintenance with their

NOTE Confidence: 0.818044066429138
00:03:55.966 --> 00:03:59.230 usual 20 day cycles for up to two years,
NOTE Confidence: 0.818044066429138
00:03:59.230 --> 00:04:00.778 followed by observation at
NOTE Confidence: 0.818044066429138
00:04:00.778 --> 00:04:02.326 every three month interval,
NOTE Confidence: 0.818044066429138
00:04:02.330 --> 00:04:04.710 with annual staging imaging.
NOTE Confidence: 0.818044066429138
00:04:04.710 --> 00:04:07.090 Patients in this protocol.
NOTE Confidence: 0.818044066429138
00:04:07.090 --> 00:04:09.110 Preceded with stem cell harvest.
NOTE Confidence: 0.818044066429138
00:04:09.110 --> 00:04:11.120 After four cycles of therapy,
NOTE Confidence: 0.818044066429138
00:04:11.120 --> 00:04:14.060 bone marrow was monitored for MRD
NOTE Confidence: 0.818044066429138
00:04:14.060 --> 00:04:16.591 assessment with flow cytometry and
NOTE Confidence: 0.818044066429138
00:04:16.591 --> 00:04:19.531 PET CT scan imaging was incorporated
NOTE Confidence: 0.818044066429138
00:04:19.531 --> 00:04:22.288 for response assessment at the end
NOTE Confidence: 0.818044066429138
00:04:22.288 --> 00:04:24.298 of induction and then annually.
NOTE Confidence: 0.818044066429138
00:04:24.300 --> 00:04:26.838 Overall, 54 patients enrolled and treated.
NOTE Confidence: 0.818044066429138
00:04:26.840 --> 00:04:28.960 And what's what's interesting is
NOTE Confidence: 0.818044066429138
00:04:28.960 --> 00:04:31.522 that 37% of patients displayed high
NOTE Confidence: 0.818044066429138

00:04:31.522 --> 00:04:33.662 risk cytogenetic features and all
NOTE Confidence: 0.818044066429138

00:04:33.662 --> 00:04:36.168 of the patients met criteria for
NOTE Confidence: 0.818044066429138

00:04:36.168 --> 00:04:38.673 high risk smoldering based on these
NOTE Confidence: 0.818044066429138

00:04:38.673 --> 00:04:40.813 definitions and what's remarkable with
NOTE Confidence: 0.818044066429138

00:04:40.813 --> 00:04:43.450 this study is that sustained MRD,
NOTE Confidence: 0.818044066429138

00:04:43.450 --> 00:04:45.750 negative complete remission rates were
NOTE Confidence: 0.818044066429138

00:04:45.750 --> 00:04:49.204 on the order of 70% in this cohort and
NOTE Confidence: 0.818044066429138

00:04:49.204 --> 00:04:52.709 at two years and five years of survival,
NOTE Confidence: 0.818044066429138

00:04:52.710 --> 00:04:54.406 sustained MRD negative complete
NOTE Confidence: 0.818044066429138

00:04:54.406 --> 00:04:56.526 responses remained at 1779 and
NOTE Confidence: 0.818044066429138

00:04:56.526 --> 00:04:59.230 53% of patients respectively.
NOTE Confidence: 0.818044066429138

00:04:59.230 --> 00:05:01.385 And overall response rates with
NOTE Confidence: 0.818044066429138

00:05:01.385 --> 00:05:03.972 this regimen were 100% with 72%
NOTE Confidence: 0.818044066429138

00:05:03.972 --> 00:05:05.696 achieving complete response and
NOTE Confidence: 0.818044066429138

00:05:05.696 --> 00:05:08.280 94% of very good partial response.
NOTE Confidence: 0.818044066429138

00:05:08.280 --> 00:05:10.004 Overall survival and progression

NOTE Confidence: 0.818044066429138

00:05:10.004 --> 00:05:12.159 free survival are not reached,

NOTE Confidence: 0.818044066429138

00:05:12.160 --> 00:05:14.320 but at 80 or milestone,

NOTE Confidence: 0.818044066429138

00:05:14.320 --> 00:05:16.900 91% of patients remain progression free.

NOTE Confidence: 0.818044066429138

00:05:16.900 --> 00:05:19.486 The treatment emergent adverse events were,

NOTE Confidence: 0.818044066429138

00:05:19.490 --> 00:05:22.076 as would be expected for this

NOTE Confidence: 0.818044066429138

00:05:22.076 --> 00:05:22.938 triplet combination.

NOTE Confidence: 0.818044066429138

00:05:22.940 --> 00:05:23.371 Specifically,

NOTE Confidence: 0.818044066429138

00:05:23.371 --> 00:05:26.388 side effects of special interest in the

NOTE Confidence: 0.818044066429138

00:05:26.388 --> 00:05:29.447 form of cardiac toxicity were seen in.

NOTE Confidence: 0.818044066429138

00:05:29.450 --> 00:05:31.880 Only two 2 patients with heart

NOTE Confidence: 0.818044066429138

00:05:31.880 --> 00:05:34.183 failure and 4% of this population.

NOTE Confidence: 0.818044066429138

00:05:34.183 --> 00:05:36.349 So overall this data show that

NOTE Confidence: 0.818044066429138

00:05:36.349 --> 00:05:37.712 carfilzomib REVLIMID dexamethasone

NOTE Confidence: 0.818044066429138

00:05:37.712 --> 00:05:39.580 regimen is highly potent.

NOTE Confidence: 0.818044066429138

00:05:39.580 --> 00:05:43.216 An leads to very deep responses in high risk,

NOTE Confidence: 0.818044066429138

00:05:43.220 --> 00:05:44.564 smoldering multiple myeloma.
NOTE Confidence: 0.818044066429138

00:05:44.564 --> 00:05:46.804 Providing further background for this
NOTE Confidence: 0.818044066429138

00:05:46.804 --> 00:05:48.809 evolving treatment landscape for early
NOTE Confidence: 0.818044066429138

00:05:48.809 --> 00:05:50.915 intervention and treatment of high risk,
NOTE Confidence: 0.818044066429138

00:05:50.920 --> 00:05:53.902 smoldering patients who have high risk of
NOTE Confidence: 0.818044066429138

00:05:53.902 --> 00:05:57.082 progression of greater than 75% / 2 years.
NOTE Confidence: 0.818044066429138

00:05:57.082 --> 00:05:59.686 Next I would like to highlight
NOTE Confidence: 0.818044066429138

00:05:59.686 --> 00:06:03.107 the updates on the grieving trial,
NOTE Confidence: 0.818044066429138

00:06:03.110 --> 00:06:05.014 Griffin trial, early safety,
NOTE Confidence: 0.818044066429138

00:06:05.014 --> 00:06:07.394 and efficacy data were published
NOTE Confidence: 0.818044066429138

00:06:07.394 --> 00:06:09.580 in 2020 in Blood Journal,
NOTE Confidence: 0.818044066429138

00:06:09.580 --> 00:06:11.352 and as you know,
NOTE Confidence: 0.818044066429138

00:06:11.352 --> 00:06:14.010 this combination of this trial compare
NOTE Confidence: 0.818044066429138

00:06:14.100 --> 00:06:17.052 daratumumab over RVD compared to the
NOTE Confidence: 0.818044066429138

00:06:17.052 --> 00:06:19.750 old RVD triplet standard of care.
NOTE Confidence: 0.818044066429138

00:06:19.750 --> 00:06:22.546 This update focuses on the data

NOTE Confidence: 0.818044066429138
00:06:22.546 --> 00:06:24.830 on overall responses and MRD,
NOTE Confidence: 0.818044066429138
00:06:24.830 --> 00:06:27.488 negative responses at the end of
NOTE Confidence: 0.818044066429138
00:06:27.488 --> 00:06:29.960 12 months of maintenance therapy.
NOTE Confidence: 0.818044066429138
00:06:29.960 --> 00:06:31.156 So as you know,
NOTE Confidence: 0.818044066429138
00:06:31.156 --> 00:06:32.651 the trial enrolled patients with
NOTE Confidence: 0.818044066429138
00:06:32.651 --> 00:06:34.318 newly diagnosed transplant eligible
NOTE Confidence: 0.818044066429138
00:06:34.318 --> 00:06:36.503 multiple myeloma with good performance
NOTE Confidence: 0.818044066429138
00:06:36.503 --> 00:06:38.880 status and preserved kidney function.
NOTE Confidence: 0.818044066429138
00:06:38.880 --> 00:06:41.610 Patients were randomized in one to one
NOTE Confidence: 0.818044066429138
00:06:41.610 --> 00:06:44.319 fashion to either old standard of care,
NOTE Confidence: 0.818044066429138
00:06:44.320 --> 00:06:46.260 RVD or they daratumumab CD.
NOTE Confidence: 0.818044066429138
00:06:46.260 --> 00:06:48.195 38 monoclonal antibody in combination
NOTE Confidence: 0.818044066429138
00:06:48.195 --> 00:06:49.743 with standard RVD triplet.
NOTE Confidence: 0.818044066429138
00:06:49.750 --> 00:06:51.455 After four cycles of induction
NOTE Confidence: 0.818044066429138
00:06:51.455 --> 00:06:53.160 therapy patients went on to
NOTE Confidence: 0.834181904792786

00:06:53.218 --> 00:06:55.568 receive autologous stem cell transplant.
NOTE Confidence: 0.834181904792786

00:06:55.570 --> 00:06:58.690 This was followed by two more cycles of
NOTE Confidence: 0.834181904792786

00:06:58.690 --> 00:07:01.010 consolidation therapy with the same regiment.
NOTE Confidence: 0.834181904792786

00:07:01.010 --> 00:07:03.242 Followed by REVLIMID maintenance as a
NOTE Confidence: 0.834181904792786

00:07:03.242 --> 00:07:05.909 single agent as per standard of care.
NOTE Confidence: 0.834181904792786

00:07:05.910 --> 00:07:07.522 Versus daratumumab REVLIMID combination
NOTE Confidence: 0.834181904792786

00:07:07.522 --> 00:07:09.537 as maintenance strategy and as
NOTE Confidence: 0.834181904792786

00:07:09.537 --> 00:07:11.579 you can see with ongoing therapy,
NOTE Confidence: 0.834181904792786

00:07:11.580 --> 00:07:14.604 responses depend at the end of 12 months
NOTE Confidence: 0.834181904792786

00:07:14.604 --> 00:07:16.874 of maintenance with Dara, RVD regimen.
NOTE Confidence: 0.834181904792786

00:07:16.874 --> 00:07:18.759 63% of patients achieved stringent
NOTE Confidence: 0.834181904792786

00:07:18.759 --> 00:07:19.513 complete responses,
NOTE Confidence: 0.834181904792786

00:07:19.520 --> 00:07:21.455 and this was significantly better
NOTE Confidence: 0.834181904792786

00:07:21.455 --> 00:07:24.171 as compared with RVD triplet and in
NOTE Confidence: 0.834181904792786

00:07:24.171 --> 00:07:26.307 general response rates and depth of
NOTE Confidence: 0.834181904792786

00:07:26.307 --> 00:07:28.210 responses were greater with Dara,

NOTE Confidence: 0.834181904792786

00:07:28.210 --> 00:07:30.856 RVD regimen at all treatment time points,

NOTE Confidence: 0.834181904792786

00:07:30.860 --> 00:07:33.724 and the same is true for the sustained

NOTE Confidence: 0.834181904792786

00:07:33.724 --> 00:07:35.708 MRD negativity lasting for greater

NOTE Confidence: 0.834181904792786

00:07:35.708 --> 00:07:38.096 than six months and greater than.

NOTE Confidence: 0.834181904792786

00:07:38.100 --> 00:07:40.698 12 months with RVD regimen compared

NOTE Confidence: 0.834181904792786

00:07:40.698 --> 00:07:41.997 to the triplet.

NOTE Confidence: 0.838071703910828

00:07:44.300 --> 00:07:47.174 The 24 months progression free survival

NOTE Confidence: 0.838071703910828

00:07:47.174 --> 00:07:49.908 and overall survival data are reported

NOTE Confidence: 0.838071703910828

00:07:49.908 --> 00:07:52.860 and at this time point and follow up.

NOTE Confidence: 0.838071703910828

00:07:52.860 --> 00:07:54.572 These are not significantly

NOTE Confidence: 0.838071703910828

00:07:54.572 --> 00:07:55.428 different statistically,

NOTE Confidence: 0.838071703910828

00:07:55.430 --> 00:07:57.570 between the two arms, however,

NOTE Confidence: 0.838071703910828

00:07:57.570 --> 00:07:59.278 predicted PFS appears promising.

NOTE Confidence: 0.838071703910828

00:07:59.278 --> 00:08:02.274 As you can see, the overall survival

NOTE Confidence: 0.838071703910828

00:08:02.274 --> 00:08:03.997 curves are overlapping, however,

NOTE Confidence: 0.838071703910828

00:08:03.997 --> 00:08:07.493 more more time and follow up is required
NOTE Confidence: 0.838071703910828

00:08:07.493 --> 00:08:10.405 for further read out of the data.
NOTE Confidence: 0.838071703910828

00:08:10.410 --> 00:08:12.118 With regard to treatment,
NOTE Confidence: 0.838071703910828

00:08:12.118 --> 00:08:13.399 emerging adverse events,
NOTE Confidence: 0.838071703910828

00:08:13.400 --> 00:08:14.669 the hematologic toxicity.
NOTE Confidence: 0.838071703910828

00:08:14.669 --> 00:08:16.784 Of grade three and four
NOTE Confidence: 0.838071703910828

00:08:16.784 --> 00:08:18.738 degree were higher in Dara,
NOTE Confidence: 0.838071703910828

00:08:18.740 --> 00:08:20.750 RVD treatment arm as compared
NOTE Confidence: 0.838071703910828

00:08:20.750 --> 00:08:22.358 to the RVD triplet.
NOTE Confidence: 0.838071703910828

00:08:22.360 --> 00:08:24.862 Other non hematologic toxicities or also
NOTE Confidence: 0.838071703910828

00:08:24.862 --> 00:08:27.578 slightly higher compared to the RVD triplet,
NOTE Confidence: 0.838071703910828

00:08:27.580 --> 00:08:28.705 especially the upper.
NOTE Confidence: 0.838071703910828

00:08:28.705 --> 00:08:30.580 Story infections were higher with
NOTE Confidence: 0.838071703910828

00:08:30.580 --> 00:08:32.410 quadruplet versus triplet combination,
NOTE Confidence: 0.838071703910828

00:08:32.410 --> 00:08:35.217 however, when it comes to grade 3.
NOTE Confidence: 0.838071703910828

00:08:35.220 --> 00:08:36.828 Four pulmonary side effects

NOTE Confidence: 0.838071703910828
00:08:36.828 --> 00:08:38.436 such as severe pneumonia,
NOTE Confidence: 0.838071703910828
00:08:38.440 --> 00:08:40.044 they were not statistically
NOTE Confidence: 0.838071703910828
00:08:40.044 --> 00:08:40.846 significantly different,
NOTE Confidence: 0.838071703910828
00:08:40.850 --> 00:08:42.860 so this regimen based on
NOTE Confidence: 0.838071703910828
00:08:42.860 --> 00:08:44.870 this face to randomize study,
NOTE Confidence: 0.838071703910828
00:08:44.870 --> 00:08:46.510 offers a very potent
NOTE Confidence: 0.838071703910828
00:08:46.510 --> 00:08:47.740 frontline induction regimen.
NOTE Confidence: 0.838071703910828
00:08:47.740 --> 00:08:49.966 Which has been adopted in clinical
NOTE Confidence: 0.838071703910828
00:08:49.966 --> 00:08:51.450 practice as their reasonable
NOTE Confidence: 0.838071703910828
00:08:51.513 --> 00:08:53.281 frontline regiment for newly
NOTE Confidence: 0.838071703910828
00:08:53.281 --> 00:08:55.491 diagnosed patients who are transplant
NOTE Confidence: 0.838071703910828
00:08:55.491 --> 00:08:57.289 eligible with multiple myeloma.
NOTE Confidence: 0.838071703910828
00:08:57.290 --> 00:09:00.202 Next I would like to highlight the
NOTE Confidence: 0.838071703910828
00:09:00.202 --> 00:09:03.156 updates of the Forte trial presented
NOTE Confidence: 0.838071703910828
00:09:03.156 --> 00:09:06.384 by Doctor Francesca Gay from Italy.
NOTE Confidence: 0.838071703910828

00:09:06.390 --> 00:09:07.635 As you know,
NOTE Confidence: 0.838071703910828

00:09:07.635 --> 00:09:10.125 40 trial randomized 474 patients with
NOTE Confidence: 0.838071703910828

00:09:10.125 --> 00:09:12.618 newly diagnosed multiple myeloma.
NOTE Confidence: 0.838071703910828

00:09:12.620 --> 00:09:15.200 These were transplant eligible an
NOTE Confidence: 0.838071703910828

00:09:15.200 --> 00:09:19.154 younger than 65 years of age and they
NOTE Confidence: 0.838071703910828

00:09:19.154 --> 00:09:22.680 were randomized to one of the three arms,
NOTE Confidence: 0.838071703910828

00:09:22.680 --> 00:09:23.636 either carfilzomib,
NOTE Confidence: 0.838071703910828

00:09:23.636 --> 00:09:24.114 cyclophosphamide,
NOTE Confidence: 0.838071703910828

00:09:24.114 --> 00:09:26.026 dexamethasone or carfilzomib REVLIMID.
NOTE Confidence: 0.838071703910828

00:09:26.030 --> 00:09:27.830 Dexamethasone followed by transplant.
NOTE Confidence: 0.838071703910828

00:09:27.830 --> 00:09:29.630 Or carfilzomib REVLIMID dexamethasone
NOTE Confidence: 0.838071703910828

00:09:29.630 --> 00:09:32.167 for 12 cycles without autologous stem
NOTE Confidence: 0.838071703910828

00:09:32.167 --> 00:09:34.537 cell transplant and at the randomization.
NOTE Confidence: 0.838071703910828

00:09:34.540 --> 00:09:37.174 Part 2 patients with randomized to
NOTE Confidence: 0.838071703910828

00:09:37.174 --> 00:09:39.853 either single agent REVLIMID as per
NOTE Confidence: 0.838071703910828

00:09:39.853 --> 00:09:42.403 standard of care or combination of

NOTE Confidence: 0.838071703910828
00:09:42.403 --> 00:09:44.718 carfilzomib produce some inhibitor with
NOTE Confidence: 0.838071703910828
00:09:44.718 --> 00:09:47.502 REVLIMID as part of maintenance therapy.
NOTE Confidence: 0.838071703910828
00:09:47.510 --> 00:09:50.366 And at this 45 months of median
NOTE Confidence: 0.838071703910828
00:09:50.366 --> 00:09:53.314 follow up they sustained MRD negative
NOTE Confidence: 0.838071703910828
00:09:53.314 --> 00:09:56.566 complete responses for KRD 12 CRV
NOTE Confidence: 0.838071703910828
00:09:56.566 --> 00:09:59.782 with transplant was 68% and KRD
NOTE Confidence: 0.838071703910828
00:09:59.782 --> 00:10:02.237 412 cycles without transplant or
NOTE Confidence: 0.838071703910828
00:10:02.237 --> 00:10:06.020 54% and the same is true for the
NOTE Confidence: 0.838071703910828
00:10:06.020 --> 00:10:08.060 progression free survival data
NOTE Confidence: 0.838071703910828
00:10:08.060 --> 00:10:11.300 which favors the KRD plus autologous
NOTE Confidence: 0.838071703910828
00:10:11.300 --> 00:10:14.031 stem cell transplant at 78% and
NOTE Confidence: 0.838071703910828
00:10:14.031 --> 00:10:17.538 the next best is KRD 12 cycles.
NOTE Confidence: 0.838071703910828
00:10:17.540 --> 00:10:19.706 Where is carfilzomib,
NOTE Confidence: 0.838071703910828
00:10:19.706 --> 00:10:22.594 cyclophosphamide dexamethasone is inferior.
NOTE Confidence: 0.838071703910828
00:10:22.600 --> 00:10:25.138 And this data present overall very
NOTE Confidence: 0.838071703910828

00:10:25.138 --> 00:10:27.637 good partial response rates for the
NOTE Confidence: 0.838071703910828

00:10:27.637 --> 00:10:29.839 time point of randomization Part 2.
NOTE Confidence: 0.838071703910828

00:10:29.840 --> 00:10:33.208 As you can see the very good partial
NOTE Confidence: 0.838071703910828

00:10:33.208 --> 00:10:35.870 risk responses on the order of 9694%
NOTE Confidence: 0.838071703910828

00:10:35.870 --> 00:10:38.166 and what was observed is that MRD
NOTE Confidence: 0.838071703910828

00:10:38.166 --> 00:10:40.460 conversion rate from MRD positive to
NOTE Confidence: 0.838071703910828

00:10:40.460 --> 00:10:42.116 negative was significantly higher
NOTE Confidence: 0.838071703910828

00:10:42.116 --> 00:10:44.595 among patients who received carfilzomib
NOTE Confidence: 0.838071703910828

00:10:44.595 --> 00:10:46.947 REVLIMID combination for maintenance.
NOTE Confidence: 0.838071703910828

00:10:46.950 --> 00:10:49.470 The overall survival curves here are
NOTE Confidence: 0.838071703910828

00:10:49.470 --> 00:10:51.894 really striking for both KRD with
NOTE Confidence: 0.838071703910828

00:10:51.894 --> 00:10:54.253 transplant as well as KRD 12 regimen
NOTE Confidence: 0.838071703910828

00:10:54.253 --> 00:10:56.936 and slightly inferior for carfilzomib
NOTE Confidence: 0.838071703910828

00:10:56.936 --> 00:10:59.208 cytoxan Barbara Cytoxan regimen.
NOTE Confidence: 0.838071703910828

00:10:59.210 --> 00:11:00.156 So overall,
NOTE Confidence: 0.838071703910828

00:11:00.156 --> 00:11:02.994 this data show that carfilzomib REVLIMID

NOTE Confidence: 0.838071703910828

00:11:02.994 --> 00:11:05.126 dexamethasone induction is a very

NOTE Confidence: 0.838071703910828

00:11:05.126 --> 00:11:06.991 potent regiment for frontline therapy

NOTE Confidence: 0.838071703910828

00:11:06.991 --> 00:11:09.176 for patients with newly diagnosed

NOTE Confidence: 0.838071703910828

00:11:09.176 --> 00:11:11.912 multiple myeloma who are transplant eligible.

NOTE Confidence: 0.838071703910828

00:11:11.920 --> 00:11:12.358 Specifically,

NOTE Confidence: 0.838071703910828

00:11:12.358 --> 00:11:14.110 KRD improved with transplant,

NOTE Confidence: 0.838071703910828

00:11:14.110 --> 00:11:15.882 improved progression free survival

NOTE Confidence: 0.838071703910828

00:11:15.882 --> 00:11:18.540 as compared to the other carbs.

NOTE Confidence: 0.838071703910828

00:11:18.540 --> 00:11:21.788 And the responses were deeper and depend

NOTE Confidence: 0.838071703910828

00:11:21.788 --> 00:11:24.810 with continuous KRD maintenance regimen.

NOTE Confidence: 0.838071703910828

00:11:24.810 --> 00:11:27.066 Next I would like to highlight

NOTE Confidence: 0.838071703910828

00:11:27.066 --> 00:11:28.570 the report on the

NOTE Confidence: 0.813896238803864

00:11:28.653 --> 00:11:31.748 elderly non transplant eligible patients

NOTE Confidence: 0.813896238803864

00:11:31.748 --> 00:11:34.843 with newly diagnosed multiple myeloma.

NOTE Confidence: 0.813896238803864

00:11:34.850 --> 00:11:38.746 The phase three term Alene trial out of

NOTE Confidence: 0.813896238803864

00:11:38.746 --> 00:11:41.692 Europe presented by Doctor Thierry Facon
NOTE Confidence: 0.813896238803864

00:11:41.692 --> 00:11:45.131 who presented the data on this study
NOTE Confidence: 0.813896238803864

00:11:45.131 --> 00:11:48.317 where 705 patients were randomized to
NOTE Confidence: 0.813896238803864

00:11:48.317 --> 00:11:50.912 either exacum Abe REVLIMID, dexamethasone,
NOTE Confidence: 0.813896238803864

00:11:50.912 --> 00:11:52.916 triplet combination versus placebo.
NOTE Confidence: 0.813896238803864

00:11:52.920 --> 00:11:54.426 REVLIMID. Dexamethasone doublet
NOTE Confidence: 0.813896238803864

00:11:54.426 --> 00:11:56.936 combination in this transplant ineligible.
NOTE Confidence: 0.813896238803864

00:11:56.940 --> 00:11:58.042 Elderly population.
NOTE Confidence: 0.813896238803864

00:11:58.042 --> 00:12:00.797 And the study demonstrated median
NOTE Confidence: 0.813896238803864

00:12:00.797 --> 00:12:02.946 progression free survival of
NOTE Confidence: 0.813896238803864

00:12:02.946 --> 00:12:05.041 significantly improved to 35 months
NOTE Confidence: 0.813896238803864

00:12:05.041 --> 00:12:08.069 compared to 21 months in the triplet
NOTE Confidence: 0.813896238803864

00:12:08.069 --> 00:12:10.204 versus the tablet RRD combination.
NOTE Confidence: 0.813896238803864

00:12:10.210 --> 00:12:13.320 And this translated into deeper.
NOTE Confidence: 0.813896238803864

00:12:13.320 --> 00:12:15.200 Higher rates of deeper responses
NOTE Confidence: 0.813896238803864

00:12:15.200 --> 00:12:18.243 in the form of higher rate of very

NOTE Confidence: 0.813896238803864
00:12:18.243 --> 00:12:20.053 good partial response as well
NOTE Confidence: 0.813896238803864
00:12:20.053 --> 00:12:22.039 as higher rate of complete.
NOTE Confidence: 0.813896238803864
00:12:22.040 --> 00:12:23.556 An stringent complete remissions
NOTE Confidence: 0.813896238803864
00:12:23.556 --> 00:12:25.830 SOA based on this data exactly.
NOTE Confidence: 0.813896238803864
00:12:25.830 --> 00:12:27.732 My problem in Texas Methadone appears
NOTE Confidence: 0.813896238803864
00:12:27.732 --> 00:12:29.902 to be a reasonable frontline regiment
NOTE Confidence: 0.813896238803864
00:12:29.902 --> 00:12:31.997 for elderly newly diagnosed subjects
NOTE Confidence: 0.813896238803864
00:12:31.997 --> 00:12:34.169 who are ineligible for transplant,
NOTE Confidence: 0.813896238803864
00:12:34.170 --> 00:12:36.949 and it provides a convenient way of
NOTE Confidence: 0.813896238803864
00:12:36.949 --> 00:12:39.439 all oral combination which may be
NOTE Confidence: 0.813896238803864
00:12:39.439 --> 00:12:41.893 particularly relevant in the covid era.
NOTE Confidence: 0.813896238803864
00:12:41.900 --> 00:12:42.536 And finally,
NOTE Confidence: 0.813896238803864
00:12:42.536 --> 00:12:44.762 I would like to highlight some of
NOTE Confidence: 0.813896238803864
00:12:44.762 --> 00:12:47.187 the preclinical data which were
NOTE Confidence: 0.813896238803864
00:12:47.187 --> 00:12:49.223 presented during scientific session,
NOTE Confidence: 0.813896238803864

00:12:49.230 --> 00:12:51.666 first out of Mayo Clinic Doctor
NOTE Confidence: 0.813896238803864

00:12:51.666 --> 00:12:52.884 Bakes Eagles experience,
NOTE Confidence: 0.813896238803864

00:12:52.890 --> 00:12:55.459 who presented the role of dichro gut
NOTE Confidence: 0.813896238803864

00:12:55.459 --> 00:12:57.769 microbiome in shaping myeloma evolution.
NOTE Confidence: 0.813896238803864

00:12:57.770 --> 00:12:58.721 In this study,
NOTE Confidence: 0.813896238803864

00:12:58.721 --> 00:13:00.623 they used VK mix transgenic mice
NOTE Confidence: 0.813896238803864

00:13:00.623 --> 00:13:02.155 which spontaneously developed
NOTE Confidence: 0.813896238803864

00:13:02.155 --> 00:13:03.880 democracies and myeloma.
NOTE Confidence: 0.813896238803864

00:13:03.880 --> 00:13:06.729 The first observation was out of Italy,
NOTE Confidence: 0.813896238803864

00:13:06.730 --> 00:13:08.555 where they observed that the
NOTE Confidence: 0.813896238803864

00:13:08.555 --> 00:13:10.380 rate of progression to myeloma
NOTE Confidence: 0.813896238803864

00:13:10.449 --> 00:13:12.060 was significantly delayed.
NOTE Confidence: 0.813896238803864

00:13:12.060 --> 00:13:14.040 In the pathogen, free vivarium,
NOTE Confidence: 0.813896238803864

00:13:14.040 --> 00:13:15.568 and so Mayo Clinic,
NOTE Confidence: 0.813896238803864

00:13:15.568 --> 00:13:17.478 Arizona joined forces with Jackson
NOTE Confidence: 0.813896238803864

00:13:17.478 --> 00:13:20.166 Labs and Debrided this Miz and

NOTE Confidence: 0.813896238803864

00:13:20.166 --> 00:13:21.954 subsequently transplanted them with

NOTE Confidence: 0.813896238803864

00:13:21.954 --> 00:13:24.078 primary myeloma samples and they

NOTE Confidence: 0.813896238803864

00:13:24.078 --> 00:13:26.490 treated mice with antibiotics or not.

NOTE Confidence: 0.813896238803864

00:13:26.490 --> 00:13:28.402 And they observed significant

NOTE Confidence: 0.813896238803864

00:13:28.402 --> 00:13:30.314 percentage increase in survival

NOTE Confidence: 0.813896238803864

00:13:30.314 --> 00:13:32.740 of mice treated with antibiotics

NOTE Confidence: 0.813896238803864

00:13:32.740 --> 00:13:35.075 as compared with the control.

NOTE Confidence: 0.813896238803864

00:13:35.080 --> 00:13:37.460 Later they identified that Prevotella,

NOTE Confidence: 0.813896238803864

00:13:37.460 --> 00:13:40.897 one of the microorganisms in the gut

NOTE Confidence: 0.813896238803864

00:13:40.897 --> 00:13:42.370 microbiome significantly impacted

NOTE Confidence: 0.813896238803864

00:13:42.444 --> 00:13:44.619 the burden of multiple myeloma.

NOTE Confidence: 0.813896238803864

00:13:44.620 --> 00:13:47.404 So this data hypothesize that the

NOTE Confidence: 0.813896238803864

00:13:47.404 --> 00:13:50.310 certain micro bacteria in the gut

NOTE Confidence: 0.813896238803864

00:13:50.310 --> 00:13:52.725 microbiome such as prevotella Trib,

NOTE Confidence: 0.813896238803864

00:13:52.730 --> 00:13:54.158 actor bacteria, Bacteroides,

NOTE Confidence: 0.813896238803864

00:13:54.158 --> 00:13:56.436 and Clostridia, can provide uncontrolled.
NOTE Confidence: 0.813896238803864

00:13:56.436 --> 00:13:58.204 Stimulation of the TH.
NOTE Confidence: 0.813896238803864

00:13:58.210 --> 00:14:00.688 17 responses and regulatory T cell
NOTE Confidence: 0.813896238803864

00:14:00.688 --> 00:14:03.220 responses and this signal from got
NOTE Confidence: 0.813896238803864

00:14:03.220 --> 00:14:05.644 may translate into increased child 17.
NOTE Confidence: 0.813896238803864

00:14:05.650 --> 00:14:07.685 Another immune changes which further
NOTE Confidence: 0.813896238803864

00:14:07.685 --> 00:14:10.175 promote growth of myeloma cells and
NOTE Confidence: 0.813896238803864

00:14:10.175 --> 00:14:12.150 progression of disease and this
NOTE Confidence: 0.813896238803864

00:14:12.150 --> 00:14:14.215 concept provides important Ave for
NOTE Confidence: 0.813896238803864

00:14:14.215 --> 00:14:15.915 the therapeutic interventions for
NOTE Confidence: 0.813896238803864

00:14:15.915 --> 00:14:18.040 prevention of disease and finally
NOTE Confidence: 0.813896238803864

00:14:18.040 --> 00:14:20.494 elegant work presented by Doctor Irene
NOTE Confidence: 0.813896238803864

00:14:20.494 --> 00:14:22.977 Ghobrial of Dana Farber who performed
NOTE Confidence: 0.813896238803864

00:14:22.977 --> 00:14:25.311 single cell RNA sequencing on the
NOTE Confidence: 0.813896238803864

00:14:25.311 --> 00:14:27.446 spectrum of specimens from healthy
NOTE Confidence: 0.813896238803864

00:14:27.446 --> 00:14:30.449 volunteers to M Gus to smoldering myeloma.

NOTE Confidence: 0.813896238803864

00:14:30.450 --> 00:14:33.246 Two full blown clinical multiple myeloma

NOTE Confidence: 0.813896238803864

00:14:33.246 --> 00:14:35.636 and highlighted the composition and

NOTE Confidence: 0.813896238803864

00:14:35.636 --> 00:14:37.472 evolution of immune microenvironment

NOTE Confidence: 0.813896238803864

00:14:37.472 --> 00:14:40.248 changes during which with time and

NOTE Confidence: 0.813896238803864

00:14:40.248 --> 00:14:42.288 progression of disease there is

NOTE Confidence: 0.813896238803864

00:14:42.288 --> 00:14:44.367 significant increase in the numbers

NOTE Confidence: 0.813896238803864

00:14:44.367 --> 00:14:47.496 of regulatory T cells as well as

NOTE Confidence: 0.813896238803864

00:14:47.496 --> 00:14:49.789 increased percentage of NK cells

NOTE Confidence: 0.813896238803864

00:14:49.789 --> 00:14:51.549 that predominantly express CX,

NOTE Confidence: 0.813896238803864

00:14:51.550 --> 00:14:52.786 CR4 and CX3 CR,

NOTE Confidence: 0.813896238803864

00:14:52.786 --> 00:14:55.198 as well as increased subsets of CD16

NOTE Confidence: 0.813896238803864

00:14:55.198 --> 00:14:57.633 monocytes and this data provides

NOTE Confidence: 0.813896238803864

00:14:57.633 --> 00:14:59.094 significant background through

NOTE Confidence: 0.813896238803864

00:14:59.094 --> 00:15:01.810 which one could design immune

NOTE Confidence: 0.813896238803864

00:15:01.810 --> 00:15:03.970 therapeutic interventions to possibly

NOTE Confidence: 0.813896238803864

00:15:03.970 --> 00:15:05.050 eradicate irregular.
NOTE Confidence: 0.813896238803864

00:15:05.050 --> 00:15:06.805 Regulatory T cells and other
NOTE Confidence: 0.813896238803864

00:15:06.805 --> 00:15:08.560 immune interventions in order to
NOTE Confidence: 0.849755704402924

00:15:08.625 --> 00:15:10.469 prevent the disease progression.
NOTE Confidence: 0.849755704402924

00:15:10.470 --> 00:15:12.726 So with that I will stop and would
NOTE Confidence: 0.849755704402924

00:15:12.726 --> 00:15:15.057 ask Doctor Terry Parker to highlight
NOTE Confidence: 0.849755704402924

00:15:15.057 --> 00:15:17.187 the updates on relapse refractory
NOTE Confidence: 0.849755704402924

00:15:17.187 --> 00:15:19.370 multiple myeloma Andale amyloidosis.
NOTE Confidence: 0.849755704402924

00:15:19.370 --> 00:15:23.468 Thank you. Thank
NOTE Confidence: 0.646573901176453

00:15:23.470 --> 00:15:30.610 you to Talia.
NOTE Confidence: 0.649618208408356

00:15:52.090 --> 00:15:56.699 Unless you get the top.
NOTE Confidence: 0.720912516117096

00:15:59.420 --> 00:16:04.395 I will be reviewing updates
NOTE Confidence: 0.720912516117096

00:16:04.395 --> 00:16:09.370 from ASH and relapse refractory
NOTE Confidence: 0.720912516117096

00:16:09.547 --> 00:16:14.779 multiple myeloma anael Android.
NOTE Confidence: 0.720912516117096

00:16:14.780 --> 00:16:16.312 I have no disclosures.
NOTE Confidence: 0.720912516117096

00:16:16.312 --> 00:16:18.610 There are multiple abstracts this year

NOTE Confidence: 0.720912516117096
00:16:18.682 --> 00:16:21.197 in relapsed refractory multiple myeloma.
NOTE Confidence: 0.720912516117096
00:16:21.200 --> 00:16:23.025 They range from new combinations
NOTE Confidence: 0.720912516117096
00:16:23.025 --> 00:16:25.367 of FDA approved agents to immuno
NOTE Confidence: 0.720912516117096
00:16:25.367 --> 00:16:27.179 therapies with antibody drug,
NOTE Confidence: 0.720912516117096
00:16:27.180 --> 00:16:28.380 conjugate San, bispecific,
NOTE Confidence: 0.720912516117096
00:16:28.380 --> 00:16:29.580 T cell engager's.
NOTE Confidence: 0.720912516117096
00:16:29.580 --> 00:16:31.848 I will start by reviewing two
NOTE Confidence: 0.720912516117096
00:16:31.848 --> 00:16:32.982 abstracts utilizing currently
NOTE Confidence: 0.720912516117096
00:16:32.982 --> 00:16:35.160 FDA approved agents in selinexor.
NOTE Confidence: 0.720912516117096
00:16:35.160 --> 00:16:36.568 An easy Texas map.
NOTE Confidence: 0.720912516117096
00:16:36.568 --> 00:16:39.296 Stamp was a phase one B2 clinical
NOTE Confidence: 0.720912516117096
00:16:39.296 --> 00:16:41.956 trial that evaluated varying doses
NOTE Confidence: 0.720912516117096
00:16:41.956 --> 00:16:44.990 and dose schedules of selinexor,
NOTE Confidence: 0.720912516117096
00:16:44.990 --> 00:16:46.412 pomalidomide and dexamethasone.
NOTE Confidence: 0.720912516117096
00:16:46.412 --> 00:16:49.256 Primary objective of the trial which
NOTE Confidence: 0.720912516117096

00:16:49.256 --> 00:16:51.761 identify the recommended phase two dose
NOTE Confidence: 0.720912516117096

00:16:51.761 --> 00:16:54.100 and evaluate the overall response rate.
NOTE Confidence: 0.720912516117096

00:16:54.100 --> 00:16:56.270 65 patients were accrued 20
NOTE Confidence: 0.720912516117096

00:16:56.270 --> 00:16:58.006 at the recommended phase.
NOTE Confidence: 0.720912516117096

00:16:58.010 --> 00:16:58.922 Two dose.
NOTE Confidence: 0.720912516117096

00:16:58.922 --> 00:17:01.658 The meeting number of prior therapies
NOTE Confidence: 0.720912516117096

00:17:01.658 --> 00:17:04.086 was three and 75% of patients
NOTE Confidence: 0.720912516117096

00:17:04.086 --> 00:17:05.818 were refractory to Lenalidomide.
NOTE Confidence: 0.720912516117096

00:17:05.820 --> 00:17:08.460 The table here illustrates the very.
NOTE Confidence: 0.720912516117096

00:17:08.460 --> 00:17:11.124 Doses of weekly selinexor with the
NOTE Confidence: 0.720912516117096

00:17:11.124 --> 00:17:13.430 recommended phase two highlighted in red,
NOTE Confidence: 0.720912516117096

00:17:13.430 --> 00:17:16.328 which ends up being 60 milligrams of
NOTE Confidence: 0.720912516117096

00:17:16.328 --> 00:17:18.242 selinexor weekly comma, 4 milligrams.
NOTE Confidence: 0.720912516117096

00:17:18.242 --> 00:17:22.540 21 out of 28 days and X 40 milligrams weekly.
NOTE Confidence: 0.720912516117096

00:17:22.540 --> 00:17:25.422 The overall response rate was 54.3% in
NOTE Confidence: 0.720912516117096

00:17:25.422 --> 00:17:27.432 palm naive patients with progression

NOTE Confidence: 0.720912516117096
00:17:27.432 --> 00:17:29.570 free survival of 12.3 months.
NOTE Confidence: 0.720912516117096
00:17:29.570 --> 00:17:31.640 There overall response rate decreased
NOTE Confidence: 0.720912516117096
00:17:31.640 --> 00:17:34.050 to 35.7% and those that were
NOTE Confidence: 0.720912516117096
00:17:34.050 --> 00:17:36.025 Palmer factory in patients dosed
NOTE Confidence: 0.720912516117096
00:17:36.025 --> 00:17:38.729 at the recommended phase two dose.
NOTE Confidence: 0.720912516117096
00:17:38.730 --> 00:17:40.788 The overall response rate was 60%
NOTE Confidence: 0.720912516117096
00:17:40.790 --> 00:17:42.194 treatment related adverse events
NOTE Confidence: 0.720912516117096
00:17:42.194 --> 00:17:44.300 were similar to what has been
NOTE Confidence: 0.720912516117096
00:17:44.362 --> 00:17:45.947 seen with selinexor in Palm.
NOTE Confidence: 0.720912516117096
00:17:45.950 --> 00:17:46.982 These included nausea,
NOTE Confidence: 0.720912516117096
00:17:46.982 --> 00:17:48.358 mild depression and fatigue.
NOTE Confidence: 0.720912516117096
00:17:48.360 --> 00:17:50.558 I chose to highlight this trial as
NOTE Confidence: 0.720912516117096
00:17:50.558 --> 00:17:52.676 it presents an all oral regimen
NOTE Confidence: 0.720912516117096
00:17:52.676 --> 00:17:54.896 which is appealing to our patients,
NOTE Confidence: 0.720912516117096
00:17:54.900 --> 00:17:56.958 especially in the relapse refractory setting.
NOTE Confidence: 0.720912516117096

00:17:56.960 --> 00:17:59.696 I also wanted to point out the different
NOTE Confidence: 0.720912516117096

00:17:59.696 --> 00:18:02.120 selinexor dosing compared to the storm trial,
NOTE Confidence: 0.720912516117096

00:18:02.120 --> 00:18:04.437 which was 80 twice a week and
NOTE Confidence: 0.720912516117096

00:18:04.437 --> 00:18:05.910 the Boston clinical trial,
NOTE Confidence: 0.720912516117096

00:18:05.910 --> 00:18:07.630 which was 100 milligrams weekly.
NOTE Confidence: 0.720912516117096

00:18:07.630 --> 00:18:10.367 There was an improved overall response rate.
NOTE Confidence: 0.720912516117096

00:18:10.370 --> 00:18:12.630 Free survival compared to historical
NOTE Confidence: 0.720912516117096

00:18:12.630 --> 00:18:15.184 data with palm index which is
NOTE Confidence: 0.720912516117096

00:18:15.184 --> 00:18:16.448 31% informance respectively.
NOTE Confidence: 0.720912516117096

00:18:16.448 --> 00:18:18.544 In patients refractory to
NOTE Confidence: 0.720912516117096

00:18:18.544 --> 00:18:21.329 Lenalidomide and worked as a matter.
NOTE Confidence: 0.720912516117096

00:18:21.330 --> 00:18:23.478 Doctor Martin presented at the interim
NOTE Confidence: 0.720912516117096

00:18:23.478 --> 00:18:25.606 analysis from the Akuma trial patients
NOTE Confidence: 0.720912516117096

00:18:25.606 --> 00:18:27.825 were eligible for this trial if they
NOTE Confidence: 0.720912516117096

00:18:27.825 --> 00:18:30.288 had one to three prior lines of therapy.
NOTE Confidence: 0.720912516117096

00:18:30.290 --> 00:18:32.288 No prior history of carpal zenmap,

NOTE Confidence: 0.720912516117096
00:18:32.290 --> 00:18:35.506 and we're not refractory to anti CD 38.
NOTE Confidence: 0.720912516117096
00:18:35.510 --> 00:18:37.445 302 patients were randomized to
NOTE Confidence: 0.720912516117096
00:18:37.445 --> 00:18:38.993 receive isatuximab carfilzomib dex
NOTE Confidence: 0.720912516117096
00:18:38.993 --> 00:18:40.925 versus carfilzomib dex with the
NOTE Confidence: 0.720912516117096
00:18:40.925 --> 00:18:42.780 primary endpoint of progression free
NOTE Confidence: 0.720912516117096
00:18:42.780 --> 00:18:44.380 survival and secondary endpoints
NOTE Confidence: 0.720912516117096
00:18:44.380 --> 00:18:45.547 of overall response.
NOTE Confidence: 0.720912516117096
00:18:45.550 --> 00:18:47.926 VGP RCR emoji negativity rates from
NOTE Confidence: 0.720912516117096
00:18:47.926 --> 00:18:50.685 those not familiar East Texas map is
NOTE Confidence: 0.720912516117096
00:18:50.685 --> 00:18:53.268 an IgG one monoclonal antibody against CD.
NOTE Confidence: 0.720912516117096
00:18:53.270 --> 00:18:55.478 38 minimal residual disease was assessed
NOTE Confidence: 0.720912516117096
00:18:55.478 --> 00:18:58.670 for this trial in the bone marrow aspirates.
NOTE Confidence: 0.720912516117096
00:18:58.670 --> 00:19:01.071 If patients who achieved at least Avicii
NOTE Confidence: 0.720912516117096
00:19:01.071 --> 00:19:03.446 PR by next generation sequencing at
NOTE Confidence: 0.720912516117096
00:19:03.446 --> 00:19:06.414 10 to the minus mix sensitivity level.
NOTE Confidence: 0.720912516117096

00:19:06.420 --> 00:19:07.965 Yeah, central lab.
NOTE Confidence: 0.720912516117096

00:19:07.965 --> 00:19:11.055 The best overall response was 86.6%,
NOTE Confidence: 0.720912516117096

00:19:11.060 --> 00:19:13.375 with 72.6% of patients achieving
NOTE Confidence: 0.720912516117096

00:19:13.375 --> 00:19:15.690 AVGPR and 39.7 as CR.
NOTE Confidence: 0.720912516117096

00:19:15.690 --> 00:19:17.079 In these attacks,
NOTE Confidence: 0.720912516117096

00:19:17.079 --> 00:19:19.394 map ARM MRD negativity rates
NOTE Confidence: 0.720912516117096

00:19:19.394 --> 00:19:21.706 were 41.4% compared to 22.9%.
NOTE Confidence: 0.720912516117096

00:19:21.706 --> 00:19:25.235 The CR rate of 39.7% was felt to
NOTE Confidence: 0.720912516117096

00:19:25.235 --> 00:19:27.260 be under estimated given Eastern
NOTE Confidence: 0.720912516117096

00:19:27.260 --> 00:19:29.120 text mode interference.
NOTE Confidence: 0.720912516117096

00:19:29.120 --> 00:19:32.354 Therefore, for 27 patients with an ear,
NOTE Confidence: 0.809959650039673

00:19:32.360 --> 00:19:35.720 see are defined as a positive
NOTE Confidence: 0.809959650039673

00:19:35.720 --> 00:19:38.569 immunofixation for IgG cap on I.
NOTE Confidence: 0.809959650039673

00:19:38.570 --> 00:19:40.460 Or potential CR were evaluated.
NOTE Confidence: 0.809959650039673

00:19:40.460 --> 00:19:42.770 The Anaspec 15 of the 27 were
NOTE Confidence: 0.809959650039673

00:19:42.770 --> 00:19:45.368 found to be M protein negative.

NOTE Confidence: 0.809959650039673

00:19:45.370 --> 00:19:48.598 Increasing the CR rate to 45.8%.

NOTE Confidence: 0.809959650039673

00:19:48.600 --> 00:19:50.430 So talking points from this

NOTE Confidence: 0.809959650039673

00:19:50.430 --> 00:19:52.260 trial without the combination of

NOTE Confidence: 0.809959650039673

00:19:52.327 --> 00:19:54.372 East Texas map carfilzomib index

NOTE Confidence: 0.809959650039673

00:19:54.372 --> 00:19:56.417 resulted in improvement in overall

NOTE Confidence: 0.809959650039673

00:19:56.482 --> 00:19:58.617 response rate CR V GPR in Aberdeen.

NOTE Confidence: 0.809959650039673

00:19:58.620 --> 00:20:00.136 Negativity rates had an

NOTE Confidence: 0.809959650039673

00:20:00.136 --> 00:20:02.700 impressive CR rate of 45 point 8%.

NOTE Confidence: 0.809959650039673

00:20:02.700 --> 00:20:05.213 Again in patients with one to three

NOTE Confidence: 0.809959650039673

00:20:05.213 --> 00:20:07.518 prior lines of therapy and MRD,

NOTE Confidence: 0.809959650039673

00:20:07.520 --> 00:20:09.746 negative negative CR rate of 24%.

NOTE Confidence: 0.809959650039673

00:20:09.750 --> 00:20:11.736 MRD negativity in both arms was

NOTE Confidence: 0.809959650039673

00:20:11.736 --> 00:20:13.830 associated with a longer progression,

NOTE Confidence: 0.809959650039673

00:20:13.830 --> 00:20:15.685 free survival and the potential

NOTE Confidence: 0.809959650039673

00:20:15.685 --> 00:20:17.169 to achieve MRD negativity,

NOTE Confidence: 0.809959650039673

00:20:17.170 --> 00:20:19.075 which should be independent of
NOTE Confidence: 0.809959650039673

00:20:19.075 --> 00:20:20.218 adverse prognostic characteristics.
NOTE Confidence: 0.809959650039673

00:20:20.220 --> 00:20:22.040 Catches ISS stage three disease.
NOTE Confidence: 0.809959650039673

00:20:22.040 --> 00:20:26.370 We don't involvement or a gain of 1 Q 21.
NOTE Confidence: 0.809959650039673

00:20:26.370 --> 00:20:29.016 And moving on to the Immunotherapy's
NOTE Confidence: 0.809959650039673

00:20:29.016 --> 00:20:31.179 Doctor Kumar presented first in
NOTE Confidence: 0.809959650039673

00:20:31.179 --> 00:20:33.433 human phase one trial of MEDI 2228,
NOTE Confidence: 0.809959650039673

00:20:33.440 --> 00:20:36.032 which is an antibody drug conjugate
NOTE Confidence: 0.809959650039673

00:20:36.032 --> 00:20:37.760 that targets the extracellular
NOTE Confidence: 0.809959650039673

00:20:37.832 --> 00:20:39.337 domain of human be CMA.
NOTE Confidence: 0.809959650039673

00:20:39.340 --> 00:20:40.908 The primary endpoints were
NOTE Confidence: 0.809959650039673

00:20:40.908 --> 00:20:42.084 safety and tolerability.
NOTE Confidence: 0.809959650039673

00:20:42.090 --> 00:20:44.055 The trial enrolled 82 patients
NOTE Confidence: 0.809959650039673

00:20:44.055 --> 00:20:45.627 41 in the expansion.
NOTE Confidence: 0.809959650039673

00:20:45.630 --> 00:20:47.994 Copart two patients had great for
NOTE Confidence: 0.809959650039673

00:20:47.994 --> 00:20:50.738 thrombocytopenia at the 0.2 mix perchik dose.

NOTE Confidence: 0.809959650039673

00:20:50.740 --> 00:20:52.775 Therefore, the maximum tolerated dose

NOTE Confidence: 0.809959650039673

00:20:52.775 --> 00:20:56.238 was 0.1 for mixer cake given Q three weeks.

NOTE Confidence: 0.809959650039673

00:20:56.240 --> 00:20:57.852 Treatment related adverse events

NOTE Confidence: 0.809959650039673

00:20:57.852 --> 00:20:58.658 included photophobia.

NOTE Confidence: 0.809959650039673

00:20:58.660 --> 00:21:00.695 Thrombocytopenia rash dry on pleural

NOTE Confidence: 0.809959650039673

00:21:00.695 --> 00:21:03.080 effusion at the maximum tolerated dose,

NOTE Confidence: 0.809959650039673

00:21:03.080 --> 00:21:05.892 the overall response rate was 66% with

NOTE Confidence: 0.809959650039673

00:21:05.892 --> 00:21:08.706 the duration of response at 5.9 months.

NOTE Confidence: 0.809959650039673

00:21:08.710 --> 00:21:10.720 Unlike the currently FDA approved

NOTE Confidence: 0.809959650039673

00:21:10.720 --> 00:21:12.328 ADC of Blanton map,

NOTE Confidence: 0.809959650039673

00:21:12.330 --> 00:21:13.938 no Keratopathy was observed.

NOTE Confidence: 0.809959650039673

00:21:13.938 --> 00:21:14.340 However,

NOTE Confidence: 0.809959650039673

00:21:14.340 --> 00:21:16.890 photophobia credit 60% of patients at

NOTE Confidence: 0.809959650039673

00:21:16.890 --> 00:21:20.068 the 0.1 four make for kiddos with a

NOTE Confidence: 0.809959650039673

00:21:20.068 --> 00:21:22.780 median time to onset of two months,

NOTE Confidence: 0.809959650039673

00:21:22.780 --> 00:21:24.790 which is roughly 2 cycles.
NOTE Confidence: 0.809959650039673

00:21:24.790 --> 00:21:27.211 This did improve in 37% of
NOTE Confidence: 0.809959650039673

00:21:27.211 --> 00:21:29.266 patients and resolved in for.
NOTE Confidence: 0.809959650039673

00:21:29.270 --> 00:21:31.280 Is holding up the medication
NOTE Confidence: 0.809959650039673

00:21:31.280 --> 00:21:33.290 this agent is moving forward,
NOTE Confidence: 0.809959650039673

00:21:33.290 --> 00:21:35.920 looking at varying adjusting schedules.
NOTE Confidence: 0.809959650039673

00:21:35.920 --> 00:21:37.180 They must pass it.
NOTE Confidence: 0.809959650039673

00:21:37.180 --> 00:21:39.070 Ash this year was for the
NOTE Confidence: 0.809959650039673

00:21:39.150 --> 00:21:41.158 bispecific T cell engager's.
NOTE Confidence: 0.809959650039673

00:21:41.160 --> 00:21:43.968 This chart is adapted from 1% in by
NOTE Confidence: 0.809959650039673

00:21:43.968 --> 00:21:45.713 Doctor Chary during his educational
NOTE Confidence: 0.809959650039673

00:21:45.713 --> 00:21:47.474 session on you know, therapies.
NOTE Confidence: 0.809959650039673

00:21:47.474 --> 00:21:47.808 Here.
NOTE Confidence: 0.809959650039673

00:21:47.808 --> 00:21:49.812 I have listed all the bytes
NOTE Confidence: 0.809959650039673

00:21:49.812 --> 00:21:52.004 that RBC may targeted that were
NOTE Confidence: 0.809959650039673

00:21:52.004 --> 00:21:53.824 presented at this year's ASH.

NOTE Confidence: 0.809959650039673
00:21:53.830 --> 00:21:54.182 Therefore,
NOTE Confidence: 0.809959650039673
00:21:54.182 --> 00:21:55.942 oral abstracts and one poster
NOTE Confidence: 0.809959650039673
00:21:55.942 --> 00:21:57.350 do just time constraints.
NOTE Confidence: 0.809959650039673
00:21:57.350 --> 00:22:00.518 I will be just talking about to Clifton AB,
NOTE Confidence: 0.809959650039673
00:22:00.520 --> 00:22:04.078 which had the largest patient accrual.
NOTE Confidence: 0.809959650039673
00:22:04.080 --> 00:22:06.201 So as mentioned to custom AB is
NOTE Confidence: 0.809959650039673
00:22:06.201 --> 00:22:08.662 ABC May CD three byte 84 patients
NOTE Confidence: 0.809959650039673
00:22:08.662 --> 00:22:10.870 received an Ivy dose with 44
NOTE Confidence: 0.809959650039673
00:22:10.950 --> 00:22:13.119 receiving subcutaneous dosing.
NOTE Confidence: 0.809959650039673
00:22:13.120 --> 00:22:15.682 The median number of prior treatments
NOTE Confidence: 0.809959650039673
00:22:15.682 --> 00:22:17.972 for these patients were six and
NOTE Confidence: 0.809959650039673
00:22:17.972 --> 00:22:19.642 81% were triple class refractory.
NOTE Confidence: 0.809959650039673
00:22:19.642 --> 00:22:22.271 By that I mean they were refractory
NOTE Confidence: 0.809959650039673
00:22:22.271 --> 00:22:24.905 to an image of proteasome inhibitor,
NOTE Confidence: 0.809959650039673
00:22:24.910 --> 00:22:27.268 an anti CD 38 monoclonal antibody.
NOTE Confidence: 0.809959650039673

00:22:27.270 --> 00:22:29.400 Step up Justin was utilized prior
NOTE Confidence: 0.809959650039673

00:22:29.400 --> 00:22:32.195 to the first full dose to decrease
NOTE Confidence: 0.809959650039673

00:22:32.195 --> 00:22:34.370 the risk aside entirely syndrome.
NOTE Confidence: 0.809959650039673

00:22:34.370 --> 00:22:36.250 Notice TRS in subsequent slides,
NOTE Confidence: 0.809959650039673

00:22:36.250 --> 00:22:38.875 adverse events and no see Russ did
NOTE Confidence: 0.809959650039673

00:22:38.875 --> 00:22:41.496 occur in 55% of patients with the
NOTE Confidence: 0.809959650039673

00:22:41.496 --> 00:22:44.148 Ivy dose and in 50% receiving the
NOTE Confidence: 0.809959650039673

00:22:44.148 --> 00:22:46.482 subcutaneous dose with the median time
NOTE Confidence: 0.809959650039673

00:22:46.482 --> 00:22:49.367 to onset of one to two days respectively.
NOTE Confidence: 0.782522559165955

00:22:49.370 --> 00:22:51.995 However, no Grade 3 events were noted.
NOTE Confidence: 0.782522559165955

00:22:52.000 --> 00:22:53.125 Neurotoxicity hurting 5%
NOTE Confidence: 0.782522559165955

00:22:53.125 --> 00:22:55.000 with two Grade 3 events.
NOTE Confidence: 0.782522559165955

00:22:55.000 --> 00:22:57.324 Injection site reactions in 32 and there
NOTE Confidence: 0.782522559165955

00:22:57.324 --> 00:22:59.870 was one death attributed to pneumonia.
NOTE Confidence: 0.782522559165955

00:22:59.870 --> 00:23:02.229 The recommended phase two dose based on
NOTE Confidence: 0.782522559165955

00:23:02.229 --> 00:23:04.420 setting safety advocacy and pharmacokinetics.

NOTE Confidence: 0.782522559165955

00:23:04.420 --> 00:23:07.428 Is 1500 micrograms per kilogram at this test,

NOTE Confidence: 0.782522559165955

00:23:07.430 --> 00:23:09.680 the overall response rate was 73%,

NOTE Confidence: 0.782522559165955

00:23:09.680 --> 00:23:10.997 as outlined here,

NOTE Confidence: 0.782522559165955

00:23:10.997 --> 00:23:14.620 with the median time to responsive one month.

NOTE Confidence: 0.782522559165955

00:23:14.620 --> 00:23:16.490 So again, take home points.

NOTE Confidence: 0.782522559165955

00:23:16.490 --> 00:23:18.506 The recommended phase two dose moving

NOTE Confidence: 0.782522559165955

00:23:18.506 --> 00:23:20.361 forward will be 1500 micrograms

NOTE Confidence: 0.782522559165955

00:23:20.361 --> 00:23:22.082 per kilogram weekly, subcu.

NOTE Confidence: 0.782522559165955

00:23:22.082 --> 00:23:23.942 This was a heavily pretreated

NOTE Confidence: 0.782522559165955

00:23:23.942 --> 00:23:24.686 patient population,

NOTE Confidence: 0.782522559165955

00:23:24.690 --> 00:23:26.560 as 39% work at refractory,

NOTE Confidence: 0.782522559165955

00:23:26.560 --> 00:23:28.828 and in this patient population that

NOTE Confidence: 0.782522559165955

00:23:28.828 --> 00:23:30.660 overall response rate was 73%,

NOTE Confidence: 0.782522559165955

00:23:30.660 --> 00:23:33.272 which is very encouraging with 23% CR

NOTE Confidence: 0.782522559165955

00:23:33.272 --> 00:23:36.248 and 55% VG PR at the recommended phase,

NOTE Confidence: 0.782522559165955

00:23:36.250 --> 00:23:39.170 two dose eat at the 11 evaluable patients
NOTE Confidence: 0.782522559165955

00:23:39.170 --> 00:23:41.634 were energy negative and there's a
NOTE Confidence: 0.782522559165955

00:23:41.634 --> 00:23:43.704 potential for durable responses as
NOTE Confidence: 0.782522559165955

00:23:43.704 --> 00:23:46.259 15 out of 16 patients were alive.
NOTE Confidence: 0.782522559165955

00:23:46.260 --> 00:23:48.225 No progression at the median
NOTE Confidence: 0.782522559165955

00:23:48.225 --> 00:23:50.190 follow up at 3.9 months.
NOTE Confidence: 0.782522559165955

00:23:50.190 --> 00:23:52.170 The other two by specifics that
NOTE Confidence: 0.782522559165955

00:23:52.170 --> 00:23:54.619 I would like to highlight include
NOTE Confidence: 0.782522559165955

00:23:54.619 --> 00:23:56.727 a bispecific targeting STR.
NOTE Confidence: 0.782522559165955

00:23:56.730 --> 00:23:58.998 H5 which stands for St receptor
NOTE Confidence: 0.782522559165955

00:23:58.998 --> 00:24:02.339 homolog 5 which is a type one membrane
NOTE Confidence: 0.782522559165955

00:24:02.339 --> 00:24:04.967 protein expressed on plasma cells with
NOTE Confidence: 0.782522559165955

00:24:05.049 --> 00:24:07.068 near 100% prevalence for myeloma.
NOTE Confidence: 0.782522559165955

00:24:07.068 --> 00:24:09.744 So Savasta map is this bispecific
NOTE Confidence: 0.782522559165955

00:24:09.744 --> 00:24:11.354 antibody that targets approximately
NOTE Confidence: 0.782522559165955

00:24:11.354 --> 00:24:13.909 the domain of FCR H5 in C3.

NOTE Confidence: 0.782522559165955

00:24:13.910 --> 00:24:15.137 Given Ivy Q,

NOTE Confidence: 0.782522559165955

00:24:15.137 --> 00:24:18.000 three weeks again with one step up,

NOTE Confidence: 0.782522559165955

00:24:18.000 --> 00:24:20.060 dose 53 patients were accrued

NOTE Confidence: 0.782522559165955

00:24:20.060 --> 00:24:22.120 with 51 being a valuable.

NOTE Confidence: 0.782522559165955

00:24:22.120 --> 00:24:24.528 And 21% of now had prior PC may

NOTE Confidence: 0.782522559165955

00:24:24.528 --> 00:24:26.121 directed their adjusting schematic

NOTE Confidence: 0.782522559165955

00:24:26.121 --> 00:24:28.875 is illustrated here and the maximum

NOTE Confidence: 0.782522559165955

00:24:28.875 --> 00:24:30.910 tolerated dose was not reached.

NOTE Confidence: 0.782522559165955

00:24:30.910 --> 00:24:31.322 Therefore,

NOTE Confidence: 0.782522559165955

00:24:31.322 --> 00:24:33.794 dose escalation is on going in

NOTE Confidence: 0.782522559165955

00:24:33.794 --> 00:24:35.870 this trial safety to note 76%

NOTE Confidence: 0.782522559165955

00:24:35.870 --> 00:24:37.780 of patients did have CR,

NOTE Confidence: 0.782522559165955

00:24:37.780 --> 00:24:40.420 S 28% had another event which

NOTE Confidence: 0.782522559165955

00:24:40.420 --> 00:24:43.011 occurred in the setting of CR S

NOTE Confidence: 0.782522559165955

00:24:43.011 --> 00:24:44.731 and 23% infusion related reaction

NOTE Confidence: 0.782522559165955

00:24:44.731 --> 00:24:46.766 in individuals who received at
NOTE Confidence: 0.782522559165955

00:24:46.766 --> 00:24:48.099 3.6 milligrams step up.
NOTE Confidence: 0.782522559165955

00:24:48.100 --> 00:24:51.148 This at least a 20 milligram full dose.
NOTE Confidence: 0.782522559165955

00:24:51.150 --> 00:24:53.130 The overall response rate was.
NOTE Confidence: 0.782522559165955

00:24:53.130 --> 00:24:56.274 53% there was a 63% overall response
NOTE Confidence: 0.782522559165955

00:24:56.274 --> 00:24:59.106 rate in patients who had received
NOTE Confidence: 0.782522559165955

00:24:59.106 --> 00:25:01.599 prior PCMI directed therapies.
NOTE Confidence: 0.782522559165955

00:25:01.600 --> 00:25:03.305 So this represents a new
NOTE Confidence: 0.782522559165955

00:25:03.305 --> 00:25:04.669 target for multiple myeloma,
NOTE Confidence: 0.782522559165955

00:25:04.670 --> 00:25:06.362 with the maximum tolerated
NOTE Confidence: 0.782522559165955

00:25:06.362 --> 00:25:08.054 dose not being reached.
NOTE Confidence: 0.782522559165955

00:25:08.060 --> 00:25:08.406 Importantly,
NOTE Confidence: 0.782522559165955

00:25:08.406 --> 00:25:10.832 Seeress did occur and 76% of patients,
NOTE Confidence: 0.782522559165955

00:25:10.832 --> 00:25:13.600 but there was only one grade three event,
NOTE Confidence: 0.782522559165955

00:25:13.600 --> 00:25:15.780 which was an elevated transaminase
NOTE Confidence: 0.782522559165955

00:25:15.780 --> 00:25:17.524 that resolved encouragingly responses

NOTE Confidence: 0.782522559165955
00:25:17.524 --> 00:25:19.088 were observed in patients who
NOTE Confidence: 0.782522559165955
00:25:19.088 --> 00:25:21.393 had prior be CMA as we will need
NOTE Confidence: 0.782522559165955
00:25:21.393 --> 00:25:23.008 therapies for patients who progress
NOTE Confidence: 0.782522559165955
00:25:23.008 --> 00:25:25.324 after car T and Adcs responses
NOTE Confidence: 0.782522559165955
00:25:25.324 --> 00:25:27.564 were seen irrespective of target
NOTE Confidence: 0.782522559165955
00:25:27.564 --> 00:25:29.244 expression levels in patients
NOTE Confidence: 0.782522559165955
00:25:29.244 --> 00:25:31.386 that have been assessed to date.
NOTE Confidence: 0.782522559165955
00:25:31.390 --> 00:25:33.819 The last by specific is till cotton
NOTE Confidence: 0.782522559165955
00:25:33.819 --> 00:25:36.568 AB which binds GPRC 5D which stands
NOTE Confidence: 0.782522559165955
00:25:36.568 --> 00:25:39.022 for G protein coupled receptor family.
NOTE Confidence: 0.782522559165955
00:25:39.030 --> 00:25:41.595 See Group 5 member in D which is an
NOTE Confidence: 0.782522559165955
00:25:41.595 --> 00:25:43.876 orphan receptor whose transcript is
NOTE Confidence: 0.782522559165955
00:25:43.876 --> 00:25:46.286 expressed in primary myeloma cells.
NOTE Confidence: 0.782522559165955
00:25:46.290 --> 00:25:48.586 This again was a phase one dose
NOTE Confidence: 0.782522559165955
00:25:48.586 --> 00:25:50.141 escalation study to identify
NOTE Confidence: 0.782522559165955

00:25:50.141 --> 00:25:51.638 the recommended phase.
NOTE Confidence: 0.782522559165955

00:25:51.640 --> 00:25:53.926 Two dose then rolled 157 patients.
NOTE Confidence: 0.782522559165955

00:25:53.930 --> 00:25:55.835 102 received an Ivy dose
NOTE Confidence: 0.782522559165955

00:25:55.835 --> 00:25:57.346 and 55% cutaneous dose.
NOTE Confidence: 0.782522559165955

00:25:57.346 --> 00:25:59.584 The dose in schematic is outlined
NOTE Confidence: 0.782522559165955

00:25:59.584 --> 00:26:01.978 here with the highlighted in green.
NOTE Confidence: 0.782522559165955

00:26:01.980 --> 00:26:03.504 Being the recommended phase,
NOTE Confidence: 0.782522559165955

00:26:03.504 --> 00:26:05.790 two dose of 405 micrograms per
NOTE Confidence: 0.785416185855865

00:26:05.862 --> 00:26:07.878 kilogram and looking at key safety
NOTE Confidence: 0.785416185855865

00:26:07.878 --> 00:26:10.183 side of Henry Lee syndrome as seen
NOTE Confidence: 0.785416185855865

00:26:10.183 --> 00:26:12.540 in 68% of patients but no grade
NOTE Confidence: 0.785416185855865

00:26:12.540 --> 00:26:14.300 three at the recommended phase,
NOTE Confidence: 0.785416185855865

00:26:14.300 --> 00:26:16.925 two dose T styles duration 38 an
NOTE Confidence: 0.785416185855865

00:26:16.925 --> 00:26:18.520 injection site reaction in 21.
NOTE Confidence: 0.785416185855865

00:26:18.520 --> 00:26:20.285 The overall response rate was
NOTE Confidence: 0.785416185855865

00:26:20.285 --> 00:26:22.044 69% of the recommended phase.

NOTE Confidence: 0.785416185855865
00:26:22.044 --> 00:26:23.803 Two dose, and 200 Tupac
NOTE Confidence: 0.785416185855865
00:26:23.803 --> 00:26:25.207 refractory patients did respond.
NOTE Confidence: 0.785416185855865
00:26:25.210 --> 00:26:27.185 The medium kind response was
NOTE Confidence: 0.785416185855865
00:26:27.185 --> 00:26:29.649 one month similar to what's been
NOTE Confidence: 0.785416185855865
00:26:29.649 --> 00:26:31.709 shown with other BI specifics.
NOTE Confidence: 0.785416185855865
00:26:31.710 --> 00:26:33.696 Take her messages for this trial.
NOTE Confidence: 0.785416185855865
00:26:33.700 --> 00:26:34.657 Is that again,
NOTE Confidence: 0.785416185855865
00:26:34.657 --> 00:26:36.571 this represents another two new target
NOTE Confidence: 0.785416185855865
00:26:36.571 --> 00:26:38.660 in my lumbar for advice specific,
NOTE Confidence: 0.785416185855865
00:26:38.660 --> 00:26:40.610 it is a subcutaneous dose which
NOTE Confidence: 0.785416185855865
00:26:40.610 --> 00:26:43.300 may allow for Q two week dose sing,
NOTE Confidence: 0.785416185855865
00:26:43.300 --> 00:26:44.950 which would be more patient,
NOTE Confidence: 0.785416185855865
00:26:44.950 --> 00:26:46.870 convenient as the other bytes I've
NOTE Confidence: 0.785416185855865
00:26:46.870 --> 00:26:48.590 discussed are all weekly dosing.
NOTE Confidence: 0.785416185855865
00:26:48.590 --> 00:26:49.914 Again, responses were observed
NOTE Confidence: 0.785416185855865

00:26:49.914 --> 00:26:51.238 in heavily pretreated patients,
NOTE Confidence: 0.785416185855865

00:26:51.240 --> 00:26:52.604 including those where pepper
NOTE Confidence: 0.785416185855865

00:26:52.604 --> 00:26:54.309 factory and there's a possibility
NOTE Confidence: 0.785416185855865

00:26:54.309 --> 00:26:56.283 of durable responses as there was
NOTE Confidence: 0.785416185855865

00:26:56.283 --> 00:26:57.858 no progression at the medium,
NOTE Confidence: 0.785416185855865

00:26:57.860 --> 00:27:02.396 follow up at 3.7 months and they know.
NOTE Confidence: 0.785416185855865

00:27:02.400 --> 00:27:04.170 Have a duration of response
NOTE Confidence: 0.785416185855865

00:27:04.170 --> 00:27:05.586 that's over two years.
NOTE Confidence: 0.785416185855865

00:27:05.590 --> 00:27:07.852 The time remaining I'll just quickly
NOTE Confidence: 0.785416185855865

00:27:07.852 --> 00:27:10.498 touch upon three trials for a lamb alloy,
NOTE Confidence: 0.785416185855865

00:27:10.500 --> 00:27:12.260 two in the frontline setting
NOTE Confidence: 0.785416185855865

00:27:12.260 --> 00:27:14.020 and one in relapsed refractory.
NOTE Confidence: 0.785416185855865

00:27:14.020 --> 00:27:16.384 The Andromeda's trial was a phase
NOTE Confidence: 0.785416185855865

00:27:16.384 --> 00:27:18.522 three randomized trial for newly
NOTE Confidence: 0.785416185855865

00:27:18.522 --> 00:27:20.470 diagnosed Ale Android patients.
NOTE Confidence: 0.785416185855865

00:27:20.470 --> 00:27:22.190 Trainer idiot patients were

NOTE Confidence: 0.785416185855865

00:27:22.190 --> 00:27:24.340 randomized to receive cyber deed.

NOTE Confidence: 0.785416185855865

00:27:24.340 --> 00:27:26.140 Cytoxan process of dexamethasone

NOTE Confidence: 0.785416185855865

00:27:26.140 --> 00:27:28.390 plus or minus daratumumab which

NOTE Confidence: 0.785416185855865

00:27:28.390 --> 00:27:30.789 is a CD 38 monoclonal antibody.

NOTE Confidence: 0.785416185855865

00:27:30.790 --> 00:27:34.230 The primary endpoint of this trial was met,

NOTE Confidence: 0.785416185855865

00:27:34.230 --> 00:27:36.385 which was haematological CR at

NOTE Confidence: 0.785416185855865

00:27:36.385 --> 00:27:37.678 56.9 versus 18%.

NOTE Confidence: 0.785416185855865

00:27:37.680 --> 00:27:39.745 I want to evaluate the impact of

NOTE Confidence: 0.785416185855865

00:27:39.745 --> 00:27:41.783 achieving a deep reduction in serum

NOTE Confidence: 0.785416185855865

00:27:41.783 --> 00:27:43.955 free light chains on a composite

NOTE Confidence: 0.785416185855865

00:27:43.955 --> 00:27:45.970 endpoint of major organ deterioration

NOTE Confidence: 0.785416185855865

00:27:45.970 --> 00:27:47.960 progression free survival in order

NOTE Confidence: 0.785416185855865

00:27:47.960 --> 00:27:50.165 to evaluate at the production the

NOTE Confidence: 0.785416185855865

00:27:50.165 --> 00:27:51.970 evaluated a involved free light

NOTE Confidence: 0.785416185855865

00:27:52.037 --> 00:27:53.783 chain of less than 20 milligrams

NOTE Confidence: 0.785416185855865

00:27:53.783 --> 00:27:55.817 per liter and the difference between
NOTE Confidence: 0.785416185855865

00:27:55.817 --> 00:27:57.827 the involved versus uninvolved free
NOTE Confidence: 0.785416185855865

00:27:57.827 --> 00:28:00.675 light chain of less than 10 and what
NOTE Confidence: 0.785416185855865

00:28:00.675 --> 00:28:03.144 they showed it is patients with in
NOTE Confidence: 0.785416185855865

00:28:03.144 --> 00:28:05.797 the daratumumab arm achieved all of these.
NOTE Confidence: 0.785416185855865

00:28:05.800 --> 00:28:07.996 71.3% of patients had an involved.
NOTE Confidence: 0.785416185855865

00:28:08.000 --> 00:28:10.742 Reaching less than 20 and 65.6% had
NOTE Confidence: 0.785416185855865

00:28:10.742 --> 00:28:13.094 the difference being less than 10.
NOTE Confidence: 0.785416185855865

00:28:13.100 --> 00:28:15.452 This resulted in improved major organ
NOTE Confidence: 0.785416185855865

00:28:15.452 --> 00:28:17.020 deterioration progression free survival,
NOTE Confidence: 0.785416185855865

00:28:17.020 --> 00:28:20.415 which is illustrated in the graph here.
NOTE Confidence: 0.785416185855865

00:28:20.420 --> 00:28:22.460 So conclusion for this trial.
NOTE Confidence: 0.785416185855865

00:28:22.460 --> 00:28:24.315 The addition of daratumumab decide
NOTE Confidence: 0.785416185855865

00:28:24.315 --> 00:28:26.676 where D resulted in improvement in
NOTE Confidence: 0.785416185855865

00:28:26.676 --> 00:28:28.005 haematological response utilizing
NOTE Confidence: 0.785416185855865

00:28:28.005 --> 00:28:29.777 a variety of measurements.

NOTE Confidence: 0.785416185855865
00:28:29.780 --> 00:28:32.066 This resulted in improved rates of
NOTE Confidence: 0.785416185855865
00:28:32.066 --> 00:28:34.260 cardiac in renal organ response.
NOTE Confidence: 0.785416185855865
00:28:34.260 --> 00:28:35.072 In addition,
NOTE Confidence: 0.785416185855865
00:28:35.072 --> 00:28:36.290 haematological progression was
NOTE Confidence: 0.785416185855865
00:28:36.290 --> 00:28:38.760 improved 23 versus 47% and rates
NOTE Confidence: 0.785416185855865
00:28:38.760 --> 00:28:40.860 of cardiac arrhythmia failure will
NOTE Confidence: 0.785416185855865
00:28:40.860 --> 00:28:42.938 also improve with the addition
NOTE Confidence: 0.785416185855865
00:28:42.938 --> 00:28:45.208 of daratumumab at 3% versus 13%.
NOTE Confidence: 0.785416185855865
00:28:45.208 --> 00:28:47.153 This represents potential and you
NOTE Confidence: 0.785416185855865
00:28:47.153 --> 00:28:49.710 standard of care for these patients
NOTE Confidence: 0.785416185855865
00:28:49.710 --> 00:28:51.994 without friends. Treatment for Alienware.
NOTE Confidence: 0.785416185855865
00:28:51.994 --> 00:28:55.969 The second trial apps for Android is Cal 101,
NOTE Confidence: 0.785416185855865
00:28:55.970 --> 00:28:58.733 which is a nail Android 5 World reactive IgG.
NOTE Confidence: 0.785416185855865
00:28:58.740 --> 00:28:59.661 One monoclonal antibody.
NOTE Confidence: 0.785416185855865
00:28:59.661 --> 00:29:02.130 This was first mentioned at ASH in 2017.
NOTE Confidence: 0.785416185855865

00:29:02.130 --> 00:29:03.978 This is a phase two study.
NOTE Confidence: 0.785416185855865

00:29:03.980 --> 00:29:05.512 Determine the recommended phase
NOTE Confidence: 0.785416185855865

00:29:05.512 --> 00:29:07.810 three dose when given in combination
NOTE Confidence: 0.785416185855865

00:29:07.868 --> 00:29:09.947 with cyber DM Part A or with cyber D
NOTE Confidence: 0.785416185855865

00:29:09.947 --> 00:29:11.724 plus daratumumab in Part B patients
NOTE Confidence: 0.785416185855865

00:29:11.724 --> 00:29:13.214 were started at a dose
NOTE Confidence: 0.756147742271423

00:29:13.220 --> 00:29:15.278 of 500 mics per meter squared and
NOTE Confidence: 0.756147742271423

00:29:15.278 --> 00:29:17.142 this was escalated to the maximum
NOTE Confidence: 0.756147742271423

00:29:17.142 --> 00:29:18.978 tolerated dose with 1000 mics per
NOTE Confidence: 0.756147742271423

00:29:18.978 --> 00:29:20.897 meter squared weekly for four weeks
NOTE Confidence: 0.756147742271423

00:29:20.897 --> 00:29:22.781 and then every other week there
NOTE Confidence: 0.756147742271423

00:29:22.781 --> 00:29:24.386 were no infusion related reactions.
NOTE Confidence: 0.756147742271423

00:29:24.390 --> 00:29:26.514 Treatment related adverse events were all
NOTE Confidence: 0.756147742271423

00:29:26.514 --> 00:29:29.038 less than grade two and included rash,
NOTE Confidence: 0.756147742271423

00:29:29.040 --> 00:29:30.516 nausea, vomiting, and diarrhea.
NOTE Confidence: 0.756147742271423

00:29:30.516 --> 00:29:32.730 I've seen here also in patients

NOTE Confidence: 0.756147742271423

00:29:32.796 --> 00:29:34.800 with renal involvement had an organ

NOTE Confidence: 0.756147742271423

00:29:34.800 --> 00:29:36.558 response defined as a percent

NOTE Confidence: 0.756147742271423

00:29:36.558 --> 00:29:38.706 decrease from baseline in 24 hour

NOTE Confidence: 0.756147742271423

00:29:38.706 --> 00:29:40.854 approaching area of greater than 30%,

NOTE Confidence: 0.756147742271423

00:29:40.854 --> 00:29:43.002 and there was one cardiac response.

NOTE Confidence: 0.756147742271423

00:29:43.010 --> 00:29:44.078 I probably MP.

NOTE Confidence: 0.756147742271423

00:29:44.078 --> 00:29:46.214 So this compound is moving forward

NOTE Confidence: 0.756147742271423

00:29:46.214 --> 00:29:48.904 at the recommended Phase 3 to 7000

NOTE Confidence: 0.756147742271423

00:29:48.904 --> 00:29:50.960 mixed per meter squared weekly,

NOTE Confidence: 0.756147742271423

00:29:50.960 --> 00:29:53.640 and then times for than every other week.

NOTE Confidence: 0.756147742271423

00:29:53.640 --> 00:29:55.315 There are currently two phase

NOTE Confidence: 0.756147742271423

00:29:55.315 --> 00:29:56.320 three trials open,

NOTE Confidence: 0.756147742271423

00:29:56.320 --> 00:29:58.504 one for male stage 3B patients and

NOTE Confidence: 0.756147742271423

00:29:58.504 --> 00:30:00.679 the other for stage 3B patients,

NOTE Confidence: 0.756147742271423

00:30:00.680 --> 00:30:02.864 so I'm sure we will be hearing

NOTE Confidence: 0.756147742271423

00:30:02.864 --> 00:30:05.030 more about this compound to come.
NOTE Confidence: 0.756147742271423

00:30:05.030 --> 00:30:06.986 The last trial in relapsed refractory
NOTE Confidence: 0.756147742271423

00:30:06.986 --> 00:30:09.024 Elana Lloyd was with ice attacks
NOTE Confidence: 0.756147742271423

00:30:09.024 --> 00:30:11.046 map and this results from the
NOTE Confidence: 0.756147742271423

00:30:11.046 --> 00:30:12.740 Southwest Oncology Group 1702 trial.
NOTE Confidence: 0.756147742271423

00:30:12.740 --> 00:30:14.450 All patients who have received
NOTE Confidence: 0.756147742271423

00:30:14.450 --> 00:30:16.420 at least one prior line of.
NOTE Confidence: 0.756147742271423

00:30:16.420 --> 00:30:16.950 Therapy.
NOTE Confidence: 0.756147742271423

00:30:16.950 --> 00:30:20.660 And hadn't had one organ system involvement.
NOTE Confidence: 0.756147742271423

00:30:20.660 --> 00:30:22.495 Received text messages to 20
NOTE Confidence: 0.756147742271423

00:30:22.495 --> 00:30:23.963 minutes per meter squared.
NOTE Confidence: 0.756147742271423

00:30:23.970 --> 00:30:25.438 The primary endpoint was
NOTE Confidence: 0.756147742271423

00:30:25.438 --> 00:30:26.906 haematological overall response rate,
NOTE Confidence: 0.756147742271423

00:30:26.910 --> 00:30:29.854 which was 77% with a one year estimated.
NOTE Confidence: 0.756147742271423

00:30:29.860 --> 00:30:31.695 Overall survival of 97% when
NOTE Confidence: 0.756147742271423

00:30:31.695 --> 00:30:32.796 your estimated progression.

NOTE Confidence: 0.756147742271423

00:30:32.800 --> 00:30:34.112 Free survival of 85%.

NOTE Confidence: 0.756147742271423

00:30:34.112 --> 00:30:36.080 The safety and response data was

NOTE Confidence: 0.756147742271423

00:30:36.145 --> 00:30:37.875 similar to that previously reported

NOTE Confidence: 0.756147742271423

00:30:37.875 --> 00:30:40.109 with Darren to in our monotherapy

NOTE Confidence: 0.756147742271423

00:30:40.109 --> 00:30:42.294 in relapsed refractory Elana LA

NOTE Confidence: 0.756147742271423

00:30:42.294 --> 00:30:44.042 Justice and provides another

NOTE Confidence: 0.756147742271423

00:30:44.050 --> 00:30:45.800 treatment option for these patients.

NOTE Confidence: 0.756147742271423

00:30:45.800 --> 00:30:48.815 With that I will finish and pass it along

NOTE Confidence: 0.756147742271423

00:30:48.815 --> 00:30:51.746 to doctor Know Far Bar to finish up.

NOTE Confidence: 0.801727831363678

00:31:02.710 --> 00:31:05.657 and when the focus for the most

NOTE Confidence: 0.801727831363678

00:31:05.657 --> 00:31:09.613 part on car T cell therapies for

NOTE Confidence: 0.801727831363678

00:31:09.613 --> 00:31:12.201 relapsed refractory myeloma patients

NOTE Confidence: 0.801727831363678

00:31:12.201 --> 00:31:16.536 and then close with a few comments

NOTE Confidence: 0.801727831363678

00:31:16.536 --> 00:31:19.476 on autologous stem cell transplant

NOTE Confidence: 0.801727831363678

00:31:19.480 --> 00:31:22.920 for the newly diagnosed patients.

NOTE Confidence: 0.801727831363678

00:31:22.920 --> 00:31:25.426 So I want to remind everyone that
NOTE Confidence: 0.801727831363678

00:31:25.426 --> 00:31:27.920 patients who are we have been
NOTE Confidence: 0.801727831363678

00:31:27.920 --> 00:31:30.160 refractory to image producer members.
NOTE Confidence: 0.801727831363678

00:31:30.160 --> 00:31:32.694 An anti CD 30 antibodies have extremely
NOTE Confidence: 0.801727831363678

00:31:32.694 --> 00:31:34.580 poor prognosis with immigration,
NOTE Confidence: 0.801727831363678

00:31:34.580 --> 00:31:35.442 median progression,
NOTE Confidence: 0.801727831363678

00:31:35.442 --> 00:31:38.459 free survival of two to six months
NOTE Confidence: 0.801727831363678

00:31:38.459 --> 00:31:41.024 and most of them not living past
NOTE Confidence: 0.801727831363678

00:31:41.024 --> 00:31:43.303 one year and some terminology to
NOTE Confidence: 0.801727831363678

00:31:43.303 --> 00:31:45.799 remind you as those are refractory
NOTE Confidence: 0.801727831363678

00:31:45.799 --> 00:31:48.575 to the three classes of drugs or
NOTE Confidence: 0.801727831363678

00:31:48.575 --> 00:31:51.000 called triple or factory and those
NOTE Confidence: 0.801727831363678

00:31:51.000 --> 00:31:53.090 are refractory to two images.
NOTE Confidence: 0.801727831363678

00:31:53.090 --> 00:31:56.645 Two peas and anti clone the anti CD 38
NOTE Confidence: 0.801727831363678

00:31:56.645 --> 00:31:59.388 antibodies are called penta refractory.
NOTE Confidence: 0.801727831363678

00:31:59.390 --> 00:32:01.975 I'll be using those terminologies

NOTE Confidence: 0.801727831363678

00:32:01.975 --> 00:32:04.043 in my next slide.

NOTE Confidence: 0.801727831363678

00:32:04.050 --> 00:32:07.088 So the first study I'm going to

NOTE Confidence: 0.801727831363678

00:32:07.088 --> 00:32:09.220 be highlighting here is using

NOTE Confidence: 0.801727831363678

00:32:09.220 --> 00:32:11.817 the car T cell called Ida cell.

NOTE Confidence: 0.801727831363678

00:32:11.820 --> 00:32:12.566 In short,

NOTE Confidence: 0.801727831363678

00:32:12.566 --> 00:32:14.804 formerly known as BB 2121 an

NOTE Confidence: 0.801727831363678

00:32:14.804 --> 00:32:17.548 If you see here the construct,

NOTE Confidence: 0.801727831363678

00:32:17.550 --> 00:32:19.500 it has a binding domain against

NOTE Confidence: 0.801727831363678

00:32:19.500 --> 00:32:22.992 the CMA on the tumor cell and the

NOTE Confidence: 0.801727831363678

00:32:22.992 --> 00:32:25.112 intracellular domain includes the

NOTE Confidence: 0.801727831363678

00:32:25.112 --> 00:32:26.948 costimulatory molecule form 1B B.

NOTE Confidence: 0.801727831363678

00:32:26.950 --> 00:32:30.640 This was a phase one study and study design.

NOTE Confidence: 0.801727831363678

00:32:30.640 --> 00:32:32.180 Patients underwent local pheresis

NOTE Confidence: 0.801727831363678

00:32:32.180 --> 00:32:34.490 and then the cell product was

NOTE Confidence: 0.801727831363678

00:32:34.554 --> 00:32:35.958 taken to manufacturing.

NOTE Confidence: 0.801727831363678

00:32:35.960 --> 00:32:39.368 And then delivered back to the patient's car.

NOTE Confidence: 0.801727831363678

00:32:39.370 --> 00:32:41.920 T cell infusion before the patient

NOTE Confidence: 0.801727831363678

00:32:41.920 --> 00:32:44.475 gets the infusion, they get lifted,

NOTE Confidence: 0.801727831363678

00:32:44.475 --> 00:32:46.175 depleting therapy with food,

NOTE Confidence: 0.801727831363678

00:32:46.180 --> 00:32:47.419 European and cytoxan.

NOTE Confidence: 0.801727831363678

00:32:47.419 --> 00:32:49.484 And this is pretty routine

NOTE Confidence: 0.801727831363678

00:32:49.484 --> 00:32:51.720 schema for most Corti studies.

NOTE Confidence: 0.801727831363678

00:32:51.720 --> 00:32:54.695 In this study there were 62 patients.

NOTE Confidence: 0.801727831363678

00:32:54.700 --> 00:32:57.148 Majority of the patients received the

NOTE Confidence: 0.801727831363678

00:32:57.148 --> 00:33:00.668 1:50 and the 450 million cells per cagey.

NOTE Confidence: 0.801727831363678

00:33:00.670 --> 00:33:03.274 This was a heavily pretreated population

NOTE Confidence: 0.801727831363678

00:33:03.274 --> 00:33:06.679 with median line of prior therapy of 670%.

NOTE Confidence: 0.801727831363678

00:33:06.680 --> 00:33:10.226 Being triple refactoring 27% had high

NOTE Confidence: 0.801727831363678

00:33:10.226 --> 00:33:14.066 risk cytogenetics and 37% or high

NOTE Confidence: 0.801727831363678

00:33:14.066 --> 00:33:17.756 risk by having extramedullary disease.

NOTE Confidence: 0.801727831363678

00:33:17.760 --> 00:33:20.315 So looking at the safety and efficacy,

NOTE Confidence: 0.801727831363678

00:33:20.320 --> 00:33:22.342 all patients have cytopenias and this

NOTE Confidence: 0.801727831363678

00:33:22.342 --> 00:33:24.918 is from the link for depleting therapy

NOTE Confidence: 0.801727831363678

00:33:24.918 --> 00:33:27.246 which is routinely used for Carty.

NOTE Confidence: 0.801727831363678

00:33:27.250 --> 00:33:29.344 I'm more focusing going to be

NOTE Confidence: 0.801727831363678

00:33:29.344 --> 00:33:31.565 focusing on this CRS decided kind

NOTE Confidence: 0.801727831363678

00:33:31.565 --> 00:33:33.815 release in German that I cans,

NOTE Confidence: 0.801727831363678

00:33:33.820 --> 00:33:35.460 which is the neurotoxicity we

NOTE Confidence: 0.801727831363678

00:33:35.460 --> 00:33:37.840 see with car T cell therapies,

NOTE Confidence: 0.801727831363678

00:33:37.840 --> 00:33:40.760 so 75% of the patients had CRS with

NOTE Confidence: 0.801727831363678

00:33:40.760 --> 00:33:43.310 about 6% having Grade 3 and above.

NOTE Confidence: 0.801727831363678

00:33:43.310 --> 00:33:45.140 In terms of the neurotoxicity,

NOTE Confidence: 0.801727831363678

00:33:45.140 --> 00:33:47.695 which can manifest as an several Catholic

NOTE Confidence: 0.801727831363678

00:33:47.695 --> 00:33:50.370 picture, but can be as severe as.

NOTE Confidence: 0.801727831363678

00:33:50.370 --> 00:33:53.350 Brain edema seizures 34%.

NOTE Confidence: 0.801727831363678

00:33:53.350 --> 00:33:58.528 I can't with very rare incidents of

NOTE Confidence: 0.801727831363678

00:33:58.528 --> 00:34:03.096 having Grade 3 or above less than 2%.

NOTE Confidence: 0.801727831363678

00:34:03.100 --> 00:34:05.385 Infections are very common in

NOTE Confidence: 0.801727831363678

00:34:05.385 --> 00:34:06.756 this patient population.

NOTE Confidence: 0.801727831363678

00:34:06.760 --> 00:34:10.424 Is we all know and 75% had infections

NOTE Confidence: 0.801727831363678

00:34:10.424 --> 00:34:13.623 with 23% being Grade 3 or above.

NOTE Confidence: 0.801727831363678

00:34:13.630 --> 00:34:15.920 Now look at the efficacy,

NOTE Confidence: 0.801727831363678

00:34:15.920 --> 00:34:18.210 it's quite impressive with an

NOTE Confidence: 0.801727831363678

00:34:18.210 --> 00:34:20.500 overall response rate of 76%.

NOTE Confidence: 0.801727831363678

00:34:20.500 --> 00:34:23.248 In this relapse population with the

NOTE Confidence: 0.801727831363678

00:34:23.248 --> 00:34:26.604 CR rate of 33% at the median Phillip.

NOTE Confidence: 0.801727831363678

00:34:26.604 --> 00:34:28.890 And that the response rate was

NOTE Confidence: 0.801727831363678

00:34:28.970 --> 00:34:30.050 dose dependent.

NOTE Confidence: 0.801727831363678

00:34:30.050 --> 00:34:32.927 So with higher doses they saw a

NOTE Confidence: 0.801727831363678

00:34:32.927 --> 00:34:34.956 higher overall response rate and

NOTE Confidence: 0.801727831363678

00:34:34.956 --> 00:34:37.455 the median follow up of 18 months.

NOTE Confidence: 0.801727831363678

00:34:37.460 --> 00:34:39.550 The great meeting duration of

NOTE Confidence: 0.801727831363678

00:34:39.550 --> 00:34:42.051 response was about 10 months and

NOTE Confidence: 0.801727831363678

00:34:42.051 --> 00:34:44.085 this was not affected by age,

NOTE Confidence: 0.835485398769379

00:34:44.090 --> 00:34:45.260 extramedullary disease stage

NOTE Confidence: 0.835485398769379

00:34:45.260 --> 00:34:47.498 and 50% of responders retained

NOTE Confidence: 0.835485398769379

00:34:47.498 --> 00:34:50.414 the response at over two years.

NOTE Confidence: 0.835485398769379

00:34:50.420 --> 00:34:53.528 This graph here shows you that the

NOTE Confidence: 0.835485398769379

00:34:53.528 --> 00:34:55.742 deeper responses actually lead to

NOTE Confidence: 0.835485398769379

00:34:55.742 --> 00:34:58.142 longer duration of response with those

NOTE Confidence: 0.835485398769379

00:34:58.142 --> 00:35:01.170 with CR exemplified by the blue line.

NOTE Confidence: 0.835485398769379

00:35:01.170 --> 00:35:03.924 Here having a median duration of

NOTE Confidence: 0.835485398769379

00:35:03.924 --> 00:35:06.450 response of almost 15 months.

NOTE Confidence: 0.835485398769379

00:35:06.450 --> 00:35:09.360 The median progression free survival was

NOTE Confidence: 0.835485398769379

00:35:09.360 --> 00:35:13.066 88 months with a very impressive meeting

NOTE Confidence: 0.835485398769379

00:35:13.066 --> 00:35:16.414 overall survival of 30 four months.

NOTE Confidence: 0.835485398769379

00:35:16.420 --> 00:35:18.515 Perhaps these patients were able

NOTE Confidence: 0.835485398769379

00:35:18.515 --> 00:35:21.074 to then get further treatments to
NOTE Confidence: 0.835485398769379

00:35:21.074 --> 00:35:23.034 lead to this impressive overall
NOTE Confidence: 0.835485398769379

00:35:23.034 --> 00:35:25.410 survival in this patient population.
NOTE Confidence: 0.835485398769379

00:35:25.410 --> 00:35:27.180 The next Accardi study is the
NOTE Confidence: 0.835485398769379

00:35:27.180 --> 00:35:28.830 car to Tud one study,
NOTE Confidence: 0.835485398769379

00:35:28.830 --> 00:35:31.670 and this uses a different car T product
NOTE Confidence: 0.835485398769379

00:35:31.670 --> 00:35:34.426 called still to sell it 2 bonds to be CMA,
NOTE Confidence: 0.835485398769379

00:35:34.430 --> 00:35:36.296 but it has two binding domains.
NOTE Confidence: 0.835485398769379

00:35:36.300 --> 00:35:37.850 As you can see here,
NOTE Confidence: 0.835485398769379

00:35:37.850 --> 00:35:40.955 and it also uses a four 1B B like
NOTE Confidence: 0.835485398769379

00:35:40.955 --> 00:35:42.239 the Ida cell.
NOTE Confidence: 0.835485398769379

00:35:42.240 --> 00:35:45.312 This study there was close to
NOTE Confidence: 0.835485398769379

00:35:45.312 --> 00:35:47.902 100 patients enrolled with a
NOTE Confidence: 0.835485398769379

00:35:47.902 --> 00:35:50.566 median follow up of 12.4 months,
NOTE Confidence: 0.835485398769379

00:35:50.570 --> 00:35:52.618 also heavily pretreated population
NOTE Confidence: 0.835485398769379

00:35:52.618 --> 00:35:55.690 with the meeting lines of prior

NOTE Confidence: 0.835485398769379

00:35:55.775 --> 00:35:58.410 therapy of 687% were triple refractory

NOTE Confidence: 0.835485398769379

00:35:58.410 --> 00:36:00.860 with 42% being penta refractory.

NOTE Confidence: 0.835485398769379

00:36:00.860 --> 00:36:03.310 23% high recited genetics and

NOTE Confidence: 0.835485398769379

00:36:03.310 --> 00:36:06.869 13% and extramedullary disease.

NOTE Confidence: 0.835485398769379

00:36:06.870 --> 00:36:09.086 Now let's look at the toxicity of cell

NOTE Confidence: 0.835485398769379

00:36:09.086 --> 00:36:11.296 to cell. So very high rates of CRS.

NOTE Confidence: 0.835485398769379

00:36:11.300 --> 00:36:12.690 Nearly all patients got this,

NOTE Confidence: 0.835485398769379

00:36:12.690 --> 00:36:14.608 but for the most part they were

NOTE Confidence: 0.835485398769379

00:36:14.608 --> 00:36:16.301 grade one and grade two with

NOTE Confidence: 0.835485398769379

00:36:16.301 --> 00:36:18.230 only 5% having Grade 3 or above.

NOTE Confidence: 0.835485398769379

00:36:18.230 --> 00:36:19.338 As you can see,

NOTE Confidence: 0.835485398769379

00:36:19.338 --> 00:36:21.398 there is 70% use of totsuzen Maps,

NOTE Confidence: 0.835485398769379

00:36:21.398 --> 00:36:23.591 but they were even using the dose

NOTE Confidence: 0.835485398769379

00:36:23.591 --> 00:36:25.607 who's map for some of the great

NOTE Confidence: 0.835485398769379

00:36:25.607 --> 00:36:27.417 ones which we do sometimes do.

NOTE Confidence: 0.835485398769379

00:36:27.420 --> 00:36:30.024 I can't see Neurotoxicity was seen at
NOTE Confidence: 0.835485398769379

00:36:30.024 --> 00:36:32.997 16% with two percent Grade 3 or above,
NOTE Confidence: 0.835485398769379

00:36:33.000 --> 00:36:36.348 which is similar to the prior study as well.
NOTE Confidence: 0.835485398769379

00:36:36.350 --> 00:36:38.716 They do comment on this other nurse
NOTE Confidence: 0.835485398769379

00:36:38.716 --> 00:36:41.794 Texas City that is more delayed and also
NOTE Confidence: 0.835485398769379

00:36:41.794 --> 00:36:43.784 sometimes not reversible like that.
NOTE Confidence: 0.835485398769379

00:36:43.790 --> 00:36:46.764 I can occur in about 12% of the
NOTE Confidence: 0.835485398769379

00:36:46.764 --> 00:36:48.624 patients in this involved movement
NOTE Confidence: 0.835485398769379

00:36:48.624 --> 00:36:49.740 or neurocognitive changes.
NOTE Confidence: 0.835485398769379

00:36:49.740 --> 00:36:51.705 There are investigating this further
NOTE Confidence: 0.835485398769379

00:36:51.705 --> 00:36:54.199 in in their subsequent studies as well.
NOTE Confidence: 0.835485398769379

00:36:54.200 --> 00:36:56.839 There is 20% of Grade 3 and
NOTE Confidence: 0.835485398769379

00:36:56.839 --> 00:36:57.970 above infections an.
NOTE Confidence: 0.835485398769379

00:36:57.970 --> 00:36:59.090 Of their 14 deaths,
NOTE Confidence: 0.835485398769379

00:36:59.090 --> 00:37:01.164 6 or related to sell to sell
NOTE Confidence: 0.835485398769379

00:37:01.164 --> 00:37:03.120 what stands out in this study.

NOTE Confidence: 0.835485398769379

00:37:03.120 --> 00:37:05.613 It also is that there was a later onset

NOTE Confidence: 0.835485398769379

00:37:05.613 --> 00:37:08.282 of CR S with a median of seven days

NOTE Confidence: 0.835485398769379

00:37:08.282 --> 00:37:10.388 compared to two and other studies.

NOTE Confidence: 0.835485398769379

00:37:10.390 --> 00:37:12.514 They hypothesize this is because of

NOTE Confidence: 0.835485398769379

00:37:12.514 --> 00:37:15.140 the timing of the T cell expansion.

NOTE Confidence: 0.835485398769379

00:37:15.140 --> 00:37:17.726 Now the efficacy is very impressive,

NOTE Confidence: 0.835485398769379

00:37:17.730 --> 00:37:19.880 with an overall response rate

NOTE Confidence: 0.835485398769379

00:37:19.880 --> 00:37:22.033 almost 196.9% with the stringent

NOTE Confidence: 0.835485398769379

00:37:22.033 --> 00:37:25.480 CR of 67% on high rates of MRD,

NOTE Confidence: 0.835485398769379

00:37:25.480 --> 00:37:27.204 negativity responses are ongoing

NOTE Confidence: 0.835485398769379

00:37:27.204 --> 00:37:28.888 in 72% of patients.

NOTE Confidence: 0.835485398769379

00:37:28.888 --> 00:37:30.933 They have not reached their

NOTE Confidence: 0.835485398769379

00:37:30.933 --> 00:37:32.810 median progression free survival,

NOTE Confidence: 0.835485398769379

00:37:32.810 --> 00:37:35.432 and they estimated the 12 month

NOTE Confidence: 0.835485398769379

00:37:35.432 --> 00:37:37.550 progression free survival at 76%.

NOTE Confidence: 0.835485398769379

00:37:37.550 --> 00:37:40.520 As you can see here by the next graph

NOTE Confidence: 0.835485398769379

00:37:40.520 --> 00:37:42.980 that the progression free survival

NOTE Confidence: 0.835485398769379

00:37:42.980 --> 00:37:46.046 was improved for those patients who

NOTE Confidence: 0.835485398769379

00:37:46.133 --> 00:37:48.809 were in deeper response like that.

NOTE Confidence: 0.835485398769379

00:37:48.810 --> 00:37:52.494 Sponse as opposed to the very

NOTE Confidence: 0.835485398769379

00:37:52.494 --> 00:37:54.336 good partial response.

NOTE Confidence: 0.835485398769379

00:37:54.340 --> 00:37:54.727 So.

NOTE Confidence: 0.835485398769379

00:37:54.727 --> 00:37:57.049 I've showed you two Carty studies

NOTE Confidence: 0.835485398769379

00:37:57.049 --> 00:37:59.709 that have very impressive results.

NOTE Confidence: 0.835485398769379

00:37:59.710 --> 00:38:00.070 However,

NOTE Confidence: 0.835485398769379

00:38:00.070 --> 00:38:01.870 there is still room for

NOTE Confidence: 0.835485398769379

00:38:01.870 --> 00:38:03.310 improvement on car T

NOTE Confidence: 0.823268830776215

00:38:03.387 --> 00:38:04.339 cell products.

NOTE Confidence: 0.823268830776215

00:38:04.340 --> 00:38:06.270 Of course, not everyone responds.

NOTE Confidence: 0.823268830776215

00:38:06.270 --> 00:38:07.950 Not everyone responses deeply,

NOTE Confidence: 0.823268830776215

00:38:07.950 --> 00:38:10.050 and we still have significant

NOTE Confidence: 0.823268830776215

00:38:10.050 --> 00:38:12.056 toxicity that we need to mitigate.

NOTE Confidence: 0.823268830776215

00:38:12.060 --> 00:38:15.309 So not all T cells are created equal as

NOTE Confidence: 0.823268830776215

00:38:15.309 --> 00:38:18.617 you move toward the more early T cell,

NOTE Confidence: 0.823268830776215

00:38:18.620 --> 00:38:20.936 the T cells in earlier development,

NOTE Confidence: 0.823268830776215

00:38:20.940 --> 00:38:24.405 for example, like the steps on memory T cell,

NOTE Confidence: 0.823268830776215

00:38:24.410 --> 00:38:25.586 these memory like.

NOTE Confidence: 0.823268830776215

00:38:25.586 --> 00:38:27.154 Cells have certain qualities

NOTE Confidence: 0.823268830776215

00:38:27.154 --> 00:38:29.100 that make them attractive.

NOTE Confidence: 0.823268830776215

00:38:29.100 --> 00:38:30.279 There long lived.

NOTE Confidence: 0.823268830776215

00:38:30.279 --> 00:38:32.637 They have ability to self renewal

NOTE Confidence: 0.823268830776215

00:38:32.637 --> 00:38:35.242 and in others Carty studies these

NOTE Confidence: 0.823268830776215

00:38:35.242 --> 00:38:37.948 memory like T cells correlated with

NOTE Confidence: 0.823268830776215

00:38:37.948 --> 00:38:40.388 peak expansion and sustain response.

NOTE Confidence: 0.823268830776215

00:38:40.390 --> 00:38:40.850 Additionally,

NOTE Confidence: 0.823268830776215

00:38:40.850 --> 00:38:42.690 there's potential for less

NOTE Confidence: 0.823268830776215

00:38:42.690 --> 00:38:44.530 toxicity because there's gradual
NOTE Confidence: 0.823268830776215

00:38:44.530 --> 00:38:46.028 differentiation into the effectors,
NOTE Confidence: 0.823268830776215

00:38:46.030 --> 00:38:48.820 thus more gradual tumor killing
NOTE Confidence: 0.823268830776215

00:38:48.820 --> 00:38:52.480 and perhaps less static on release.
NOTE Confidence: 0.823268830776215

00:38:52.480 --> 00:38:54.808 So this concept was used in
NOTE Confidence: 0.823268830776215

00:38:54.808 --> 00:38:57.530 the next study that PBC MA 101
NOTE Confidence: 0.823268830776215

00:38:57.530 --> 00:38:59.335 prime Phase 1 two study.
NOTE Confidence: 0.823268830776215

00:38:59.340 --> 00:39:01.620 They use this technology called piggyback,
NOTE Confidence: 0.823268830776215

00:39:01.620 --> 00:39:02.763 which preferentially makes
NOTE Confidence: 0.823268830776215

00:39:02.763 --> 00:39:04.668 stem cell memory T cells.
NOTE Confidence: 0.823268830776215

00:39:04.670 --> 00:39:06.194 It's made with transposons,
NOTE Confidence: 0.823268830776215

00:39:06.194 --> 00:39:08.480 which are plasmids instead of lentivirus,
NOTE Confidence: 0.823268830776215

00:39:08.480 --> 00:39:10.385 which is what the prior
NOTE Confidence: 0.823268830776215

00:39:10.385 --> 00:39:11.909 Carty product we're using,
NOTE Confidence: 0.823268830776215

00:39:11.910 --> 00:39:14.941 and this one has a large carrying
NOTE Confidence: 0.823268830776215

00:39:14.941 --> 00:39:17.317 capacity so we can deliver

NOTE Confidence: 0.823268830776215
00:39:17.317 --> 00:39:19.767 a lot of genetic material.
NOTE Confidence: 0.823268830776215
00:39:19.770 --> 00:39:23.434 This too was directed against BCM of course.
NOTE Confidence: 0.823268830776215
00:39:23.440 --> 00:39:25.300 So this is the study design.
NOTE Confidence: 0.823268830776215
00:39:25.300 --> 00:39:27.470 I don't want to go into detail,
NOTE Confidence: 0.823268830776215
00:39:27.470 --> 00:39:29.950 but I want to highlight a few things.
NOTE Confidence: 0.823268830776215
00:39:29.950 --> 00:39:31.624 Not only were they looking at
NOTE Confidence: 0.823268830776215
00:39:31.624 --> 00:39:33.360 different doses who dose escalation,
NOTE Confidence: 0.823268830776215
00:39:33.360 --> 00:39:35.172 but they had the various cohorts
NOTE Confidence: 0.823268830776215
00:39:35.172 --> 00:39:36.770 as you can see here.
NOTE Confidence: 0.823268830776215
00:39:36.770 --> 00:39:38.984 Now I want to point out that there are
NOTE Confidence: 0.823268830776215
00:39:38.984 --> 00:39:41.416 using Lenalidomide in different time points,
NOTE Confidence: 0.823268830776215
00:39:41.420 --> 00:39:43.828 not only for anti tumor activity but also
NOTE Confidence: 0.823268830776215
00:39:43.828 --> 00:39:45.758 for improvement of T cell functionality.
NOTE Confidence: 0.823268830776215
00:39:45.760 --> 00:39:48.330 So what I do on the focus on is the
NOTE Confidence: 0.823268830776215
00:39:48.403 --> 00:39:51.339 response in Texas City on the 1st graph.
NOTE Confidence: 0.823268830776215

00:39:51.340 --> 00:39:53.580 Do you see different overall response rate?
NOTE Confidence: 0.823268830776215

00:39:53.580 --> 00:39:56.569 In different doses and they range from
NOTE Confidence: 0.823268830776215

00:39:56.569 --> 00:39:59.310 anywhere 40s to 70% overall response rates.
NOTE Confidence: 0.823268830776215

00:39:59.310 --> 00:40:02.517 They did not feel like there was a
NOTE Confidence: 0.823268830776215

00:40:02.517 --> 00:40:04.417 dose dependent relationship here.
NOTE Confidence: 0.823268830776215

00:40:04.420 --> 00:40:07.084 Thought that we're seeing a good
NOTE Confidence: 0.823268830776215

00:40:07.084 --> 00:40:09.353 responses even with low doses
NOTE Confidence: 0.823268830776215

00:40:09.353 --> 00:40:12.188 and marked late you see that they
NOTE Confidence: 0.823268830776215

00:40:12.188 --> 00:40:14.427 were really low rates of CRS.
NOTE Confidence: 0.823268830776215

00:40:14.430 --> 00:40:15.364 It's 17%.
NOTE Confidence: 0.823268830776215

00:40:15.364 --> 00:40:18.166 So this exemplifies how a manufacturing
NOTE Confidence: 0.823268830776215

00:40:18.166 --> 00:40:20.902 technique can manipulate the T cell
NOTE Confidence: 0.823268830776215

00:40:20.902 --> 00:40:23.052 product to optimize the toxicity
NOTE Confidence: 0.823268830776215

00:40:23.052 --> 00:40:25.639 and efficacy and potentially bring
NOTE Confidence: 0.823268830776215

00:40:25.639 --> 00:40:28.234 this cellular therapy to the
NOTE Confidence: 0.823268830776215

00:40:28.234 --> 00:40:31.620 outpatient setting at some point.

NOTE Confidence: 0.823268830776215
00:40:31.620 --> 00:40:34.564 There are potential issues with car T cells,
NOTE Confidence: 0.823268830776215
00:40:34.570 --> 00:40:34.938 right?
NOTE Confidence: 0.823268830776215
00:40:34.938 --> 00:40:37.882 So it takes time to manufacture the cells.
NOTE Confidence: 0.823268830776215
00:40:37.890 --> 00:40:40.110 Some patients don't have that time.
NOTE Confidence: 0.823268830776215
00:40:40.110 --> 00:40:42.324 You know we see this patient
NOTE Confidence: 0.823268830776215
00:40:42.324 --> 00:40:43.800 needs treatment right away.
NOTE Confidence: 0.823268830776215
00:40:43.800 --> 00:40:45.645 We can't schedule the Pheresis
NOTE Confidence: 0.823268830776215
00:40:45.645 --> 00:40:47.490 in manufacturing and so forth.
NOTE Confidence: 0.823268830776215
00:40:47.490 --> 00:40:47.870 Additionally,
NOTE Confidence: 0.823268830776215
00:40:47.870 --> 00:40:50.150 the quality of autologous T cells
NOTE Confidence: 0.823268830776215
00:40:50.150 --> 00:40:52.278 might be decreased in this relapse,
NOTE Confidence: 0.823268830776215
00:40:52.280 --> 00:40:53.760 refractory patient population and
NOTE Confidence: 0.823268830776215
00:40:53.760 --> 00:40:55.610 re treatment can be difficult,
NOTE Confidence: 0.823268830776215
00:40:55.610 --> 00:40:57.685 sometimes hard to collect enough
NOTE Confidence: 0.823268830776215
00:40:57.685 --> 00:41:00.780 cells and be able to expand them.
NOTE Confidence: 0.823268830776215

00:41:00.780 --> 00:41:03.892 So this brings us to the off the
NOTE Confidence: 0.823268830776215

00:41:03.892 --> 00:41:06.239 shelf Alo 7:15 Carty targeting
NOTE Confidence: 0.823268830776215

00:41:06.239 --> 00:41:09.676 the CMA in this Phase one study.
NOTE Confidence: 0.823268830776215

00:41:09.680 --> 00:41:12.510 This is the construct here.
NOTE Confidence: 0.823268830776215

00:41:12.510 --> 00:41:14.687 What the the two key attributes is
NOTE Confidence: 0.823268830776215

00:41:14.687 --> 00:41:17.193 a knockout of CD 52 which allows
NOTE Confidence: 0.823268830776215

00:41:17.193 --> 00:41:19.068 for selective room for depletion.
NOTE Confidence: 0.823268830776215

00:41:19.070 --> 00:41:21.290 All lymphocytes have CD 52 by
NOTE Confidence: 0.823268830776215

00:41:21.290 --> 00:41:22.770 the way and it
NOTE Confidence: 0.790965676307678

00:41:22.862 --> 00:41:25.158 also has a knock out of the
NOTE Confidence: 0.790965676307678

00:41:25.158 --> 00:41:27.579 TCR gene to eliminate GV HD.
NOTE Confidence: 0.790965676307678

00:41:27.580 --> 00:41:29.460 It used a slightly different
NOTE Confidence: 0.790965676307678

00:41:29.460 --> 00:41:30.588 regiment for Lymphodepletion,
NOTE Confidence: 0.790965676307678

00:41:30.590 --> 00:41:32.998 so it's flu side plus the anti
NOTE Confidence: 0.790965676307678

00:41:32.998 --> 00:41:36.110 CD 52 versus Cyan anti CD 52 but
NOTE Confidence: 0.790965676307678

00:41:36.110 --> 00:41:38.110 the one I'm highlighting here.

NOTE Confidence: 0.790965676307678

00:41:38.110 --> 00:41:40.873 The flu sign anti CD 52 is the one

NOTE Confidence: 0.790965676307678

00:41:40.873 --> 00:41:43.235 they're presenting now but there is

NOTE Confidence: 0.790965676307678

00:41:43.235 --> 00:41:46.108 potential for maybe a less toxic went

NOTE Confidence: 0.790965676307678

00:41:46.108 --> 00:41:48.978 for the cleaning therapy here so also

NOTE Confidence: 0.790965676307678

00:41:48.978 --> 00:41:50.605 heavily pretreated population and

NOTE Confidence: 0.790965676307678

00:41:50.605 --> 00:41:53.440 almost all the more pent pent Xposed

NOTE Confidence: 0.790965676307678

00:41:53.510 --> 00:41:55.890 about half of them had high recited

NOTE Confidence: 0.790965676307678

00:41:55.890 --> 00:41:58.194 genetics and 23% and extramedullary disease.

NOTE Confidence: 0.790965676307678

00:41:58.194 --> 00:42:01.190 There were 31 patients available for safety.

NOTE Confidence: 0.790965676307678

00:42:01.190 --> 00:42:04.350 And they had 47% serious with no grade.

NOTE Confidence: 0.790965676307678

00:42:04.350 --> 00:42:05.930 Three. No, I can't.

NOTE Confidence: 0.790965676307678

00:42:05.930 --> 00:42:07.510 And no GV HD.

NOTE Confidence: 0.790965676307678

00:42:07.510 --> 00:42:09.880 So a very promising toxicity profile.

NOTE Confidence: 0.790965676307678

00:42:09.880 --> 00:42:13.003 Again, this is a very good drug that I

NOTE Confidence: 0.790965676307678

00:42:13.003 --> 00:42:15.847 think we're going to see more studies

NOTE Confidence: 0.790965676307678

00:42:15.847 --> 00:42:18.845 with an more follow up will tell
NOTE Confidence: 0.790965676307678

00:42:18.845 --> 00:42:21.971 us more information, of course. Um?
NOTE Confidence: 0.790965676307678

00:42:21.971 --> 00:42:26.220 The efficacy of alacarte in 10 patients,
NOTE Confidence: 0.790965676307678

00:42:26.220 --> 00:42:28.570 so they had various doses.
NOTE Confidence: 0.790965676307678

00:42:28.570 --> 00:42:31.804 There are temptations in the dose Level
NOTE Confidence: 0.790965676307678

00:42:31.804 --> 00:42:35.599 3 and it follow up of 3.2 months.
NOTE Confidence: 0.790965676307678

00:42:35.600 --> 00:42:38.420 The overall response rate was 60%
NOTE Confidence: 0.790965676307678

00:42:38.420 --> 00:42:41.816 with a very good partial response
NOTE Confidence: 0.790965676307678

00:42:41.816 --> 00:42:44.080 or higher or 40%.
NOTE Confidence: 0.790965676307678

00:42:44.080 --> 00:42:46.060 Now on the shift gears,
NOTE Confidence: 0.790965676307678

00:42:46.060 --> 00:42:49.516 a little bit to the good old autologous
NOTE Confidence: 0.790965676307678

00:42:49.516 --> 00:42:52.499 stem cell transplant for myeloma.
NOTE Confidence: 0.790965676307678

00:42:52.500 --> 00:42:56.037 This is an update of the FM 2009 study
NOTE Confidence: 0.790965676307678

00:42:56.037 --> 00:42:59.538 that was originally presented in 2017,
NOTE Confidence: 0.790965676307678

00:42:59.540 --> 00:43:02.933 so now it's a follow up of almost 90
NOTE Confidence: 0.790965676307678

00:43:02.933 --> 00:43:06.460 months just to remind people to phase

NOTE Confidence: 0.790965676307678

00:43:06.460 --> 00:43:09.380 three study newly diagnosed patients.

NOTE Confidence: 0.790965676307678

00:43:09.380 --> 00:43:12.215 Arm A is looking at testing RVD

NOTE Confidence: 0.790965676307678

00:43:12.215 --> 00:43:14.093 induction followed by maintenance

NOTE Confidence: 0.790965676307678

00:43:14.093 --> 00:43:16.417 Lenalidomide for one year,

NOTE Confidence: 0.790965676307678

00:43:16.420 --> 00:43:19.228 and RB is RVD induction followed

NOTE Confidence: 0.790965676307678

00:43:19.228 --> 00:43:20.164 by transplant,

NOTE Confidence: 0.790965676307678

00:43:20.170 --> 00:43:22.058 followed by RBD consolidation

NOTE Confidence: 0.790965676307678

00:43:22.058 --> 00:43:23.474 and then maintenance.

NOTE Confidence: 0.790965676307678

00:43:23.480 --> 00:43:27.251 In the limit for a year so their updated

NOTE Confidence: 0.790965676307678

00:43:27.251 --> 00:43:30.041 median progression free survival was

NOTE Confidence: 0.790965676307678

00:43:30.041 --> 00:43:34.023 47.3 months in arbutus to transmit arm

NOTE Confidence: 0.790965676307678

00:43:34.023 --> 00:43:37.743 versus 35 months in the non transplant arm.

NOTE Confidence: 0.790965676307678

00:43:37.750 --> 00:43:40.696 They had very nice overall response.

NOTE Confidence: 0.790965676307678

00:43:40.700 --> 00:43:43.658 I'm sorry very nice eight year.

NOTE Confidence: 0.790965676307678

00:43:43.660 --> 00:43:44.704 Median overall survival

NOTE Confidence: 0.790965676307678

00:43:44.704 --> 00:43:46.441 about 6060% in both groups,
NOTE Confidence: 0.790965676307678

00:43:46.441 --> 00:43:48.176 so they were not difference.
NOTE Confidence: 0.790965676307678

00:43:48.180 --> 00:43:50.420 There is no difference there and I
NOTE Confidence: 0.790965676307678

00:43:50.420 --> 00:43:53.035 just want to highlight that about 1/3
NOTE Confidence: 0.790965676307678

00:43:53.035 --> 00:43:55.405 of the patients in the transplant
NOTE Confidence: 0.790965676307678

00:43:55.481 --> 00:43:57.985 arm did not relapse after 8 years of
NOTE Confidence: 0.790965676307678

00:43:57.985 --> 00:44:00.360 follow up and these are patients that
NOTE Confidence: 0.790965676307678

00:44:00.360 --> 00:44:02.100 are not being treated continuously.
NOTE Confidence: 0.790965676307678

00:44:02.100 --> 00:44:04.536 They're only getting one year of maintenance.
NOTE Confidence: 0.790965676307678

00:44:04.540 --> 00:44:06.988 This is not the practice we do here
NOTE Confidence: 0.790965676307678

00:44:06.988 --> 00:44:09.426 in America and I think there's going
NOTE Confidence: 0.790965676307678

00:44:09.426 --> 00:44:12.010 to be more information with the US
NOTE Confidence: 0.790965676307678

00:44:12.010 --> 00:44:14.642 portion of this study looking at continuous.
NOTE Confidence: 0.790965676307678

00:44:14.650 --> 00:44:17.185 REVLIMID and whether that is
NOTE Confidence: 0.790965676307678

00:44:17.185 --> 00:44:19.720 going to affect this progression.
NOTE Confidence: 0.790965676307678

00:44:19.720 --> 00:44:21.028 Free survival benefit.

NOTE Confidence: 0.790965676307678
00:44:21.028 --> 00:44:21.464 Now,
NOTE Confidence: 0.790965676307678
00:44:21.464 --> 00:44:24.568 in terms of MRD transplant did improve
NOTE Confidence: 0.790965676307678
00:44:24.568 --> 00:44:27.459 the energy negativity rate from 20 to
NOTE Confidence: 0.790965676307678
00:44:27.459 --> 00:44:30.672 about 30% and in this graph you see
NOTE Confidence: 0.790965676307678
00:44:30.672 --> 00:44:32.765 the progression free survival based
NOTE Confidence: 0.790965676307678
00:44:32.765 --> 00:44:35.740 on MRD negative state and the transplant.
NOTE Confidence: 0.790965676307678
00:44:35.740 --> 00:44:37.960 So in red you see those
NOTE Confidence: 0.790965676307678
00:44:37.960 --> 00:44:40.290 patients who are MRD negative.
NOTE Confidence: 0.790965676307678
00:44:40.290 --> 00:44:43.620 While I'm blue there emordi positive.
NOTE Confidence: 0.790965676307678
00:44:43.620 --> 00:44:46.798 And you can see that the transplant,
NOTE Confidence: 0.790965676307678
00:44:46.800 --> 00:44:49.510 exemplified by the solid line
NOTE Confidence: 0.790965676307678
00:44:49.510 --> 00:44:51.678 improved progression free survival
NOTE Confidence: 0.790965676307678
00:44:51.678 --> 00:44:54.588 even in the MRD negative patients.
NOTE Confidence: 0.790965676307678
00:44:54.590 --> 00:44:56.510 Next study I'm going to highlight
NOTE Confidence: 0.790965676307678
00:44:56.510 --> 00:44:57.790 was already presented by
NOTE Confidence: 0.776323318481445

00:44:57.848 --> 00:45:00.970 Natalia, but I want to focus on one aspect.

NOTE Confidence: 0.776323318481445

00:45:00.970 --> 00:45:02.650 Here is the Forte study.

NOTE Confidence: 0.776323318481445

00:45:02.650 --> 00:45:05.009 Not going to go into the design.

NOTE Confidence: 0.776323318481445

00:45:05.010 --> 00:45:06.474 This was already discussed,

NOTE Confidence: 0.776323318481445

00:45:06.474 --> 00:45:08.670 but one take home messages this

NOTE Confidence: 0.776323318481445

00:45:08.736 --> 00:45:10.647 so while you see in the first

NOTE Confidence: 0.776323318481445

00:45:10.647 --> 00:45:12.399 graph here the response rate,

NOTE Confidence: 0.776323318481445

00:45:12.400 --> 00:45:13.381 the response rates,

NOTE Confidence: 0.776323318481445

00:45:13.381 --> 00:45:15.670 and an MRD negative status was similar

NOTE Confidence: 0.776323318481445

00:45:15.735 --> 00:45:17.769 in KRD versus kerdi plus transplant.

NOTE Confidence: 0.776323318481445

00:45:17.770 --> 00:45:19.415 The one year sustain energy

NOTE Confidence: 0.776323318481445

00:45:19.415 --> 00:45:21.470 negativity was higher for the kerdi,

NOTE Confidence: 0.776323318481445

00:45:21.470 --> 00:45:23.425 plus transplants as you can

NOTE Confidence: 0.776323318481445

00:45:23.425 --> 00:45:25.930 see here in the second graph.

NOTE Confidence: 0.776323318481445

00:45:25.930 --> 00:45:27.740 And this translated into improved

NOTE Confidence: 0.776323318481445

00:45:27.740 --> 00:45:30.150 progression free survival for all subgroups,

NOTE Confidence: 0.776323318481445

00:45:30.150 --> 00:45:32.070 including the high risk patients.

NOTE Confidence: 0.776323318481445

00:45:32.070 --> 00:45:34.790 So I think to conclude on on this

NOTE Confidence: 0.776323318481445

00:45:34.790 --> 00:45:37.012 section is that transplant is

NOTE Confidence: 0.776323318481445

00:45:37.012 --> 00:45:39.934 still a great treatment for upfront

NOTE Confidence: 0.776323318481445

00:45:39.934 --> 00:45:42.047 patients who can tolerate it.

NOTE Confidence: 0.776323318481445

00:45:42.050 --> 00:45:45.123 And with this I will close my

NOTE Confidence: 0.776323318481445

00:45:45.123 --> 00:45:48.029 talking will move towards our Q&A.

NOTE Confidence: 0.80887359380722

00:45:50.210 --> 00:45:52.796 Great thank you know far and

NOTE Confidence: 0.80887359380722

00:45:52.800 --> 00:45:54.950 thanks everybody for beautiful presentations.

NOTE Confidence: 0.80887359380722

00:45:54.950 --> 00:45:57.967 I do not see any active questions.

NOTE Confidence: 0.80887359380722

00:45:57.970 --> 00:46:00.819 Doctor up they had an earlier question

NOTE Confidence: 0.80887359380722

00:46:00.819 --> 00:46:03.024 which I answered the smoldering

NOTE Confidence: 0.80887359380722

00:46:03.024 --> 00:46:05.294 trial date that I presented.

NOTE Confidence: 0.80887359380722

00:46:05.300 --> 00:46:07.916 Patients who are newly diagnosed as

NOTE Confidence: 0.80887359380722

00:46:07.916 --> 00:46:11.327 opposed to those in long term follow up.

NOTE Confidence: 0.80887359380722

00:46:11.330 --> 00:46:13.826 I'd like to hear opinion from
NOTE Confidence: 0.80887359380722

00:46:13.826 --> 00:46:16.014 Sabrina what's been your strategy
NOTE Confidence: 0.80887359380722

00:46:16.014 --> 00:46:18.654 in terms of managing high risk,
NOTE Confidence: 0.80887359380722

00:46:18.660 --> 00:46:20.316 smoldering patients in your?
NOTE Confidence: 0.80887359380722

00:46:20.316 --> 00:46:22.500 Practice, thank you to tell you,
NOTE Confidence: 0.80887359380722

00:46:22.500 --> 00:46:24.618 I think that's an important question,
NOTE Confidence: 0.80887359380722

00:46:24.620 --> 00:46:26.028 and obviously one where
NOTE Confidence: 0.80887359380722

00:46:26.028 --> 00:46:27.084 multiple combinations are
NOTE Confidence: 0.848489582538605

00:46:27.090 --> 00:46:29.560 being studied. You know, I think with
NOTE Confidence: 0.848489582538605

00:46:29.560 --> 00:46:31.319 the data available on Lenalidomide
NOTE Confidence: 0.848489582538605

00:46:31.320 --> 00:46:32.457 or Lenalidomide, dexamethasone.
NOTE Confidence: 0.848489582538605

00:46:32.457 --> 00:46:34.731 I think I've still had some
NOTE Confidence: 0.848489582538605

00:46:34.731 --> 00:46:37.091 pause in terms of the lack of
NOTE Confidence: 0.848489582538605

00:46:37.091 --> 00:46:38.371 overall survival data available
NOTE Confidence: 0.848489582538605

00:46:38.380 --> 00:46:40.499 in terms of benefit, you know,
NOTE Confidence: 0.848489582538605

00:46:40.500 --> 00:46:42.618 I think it's important to acknowledge

NOTE Confidence: 0.848489582538605

00:46:42.620 --> 00:46:44.738 that our discussion of treatment in

NOTE Confidence: 0.848489582538605

00:46:44.740 --> 00:46:46.850 patients who are asymptomatic is is

NOTE Confidence: 0.848489582538605

00:46:46.850 --> 00:46:48.600 very much different than patients

NOTE Confidence: 0.848489582538605

00:46:48.600 --> 00:46:50.919 who have active or clinical myeloma.

NOTE Confidence: 0.848489582538605

00:46:50.920 --> 00:46:53.661 And so I think the importance of

NOTE Confidence: 0.848489582538605

00:46:53.661 --> 00:46:55.616 overall survival benefit is really

NOTE Confidence: 0.848489582538605

00:46:55.620 --> 00:46:58.015 important to include in that discussion.

NOTE Confidence: 0.848489582538605

00:46:58.015 --> 00:47:00.850 So I would say my practice has

NOTE Confidence: 0.848489582538605

00:47:00.933 --> 00:47:03.061 been to discuss the data available,

NOTE Confidence: 0.848489582538605

00:47:03.061 --> 00:47:04.966 including the trials that are

NOTE Confidence: 0.848489582538605

00:47:04.966 --> 00:47:06.490 looking at different combinations

NOTE Confidence: 0.848489582538605

00:47:06.544 --> 00:47:07.780 outside of Lenalidomide,

NOTE Confidence: 0.848489582538605

00:47:07.780 --> 00:47:10.520 but I would say in general I

NOTE Confidence: 0.848489582538605

00:47:10.520 --> 00:47:12.972 continue to observe most patients.

NOTE Confidence: 0.848489582538605

00:47:12.972 --> 00:47:15.728 Thank you, ultimately we do need to

NOTE Confidence: 0.848489582538605

00:47:15.728 --> 00:47:17.938 understand more about the biology of
NOTE Confidence: 0.848489582538605

00:47:17.938 --> 00:47:20.134 disease of each individual case to
NOTE Confidence: 0.848489582538605

00:47:20.134 --> 00:47:22.598 address the prevention of progression.
NOTE Confidence: 0.848489582538605

00:47:22.600 --> 00:47:24.620 Another question comes through the
NOTE Confidence: 0.848489582538605

00:47:24.620 --> 00:47:27.066 chat question for I would posit
NOTE Confidence: 0.848489582538605

00:47:27.066 --> 00:47:28.466 it to Doctor Parker.
NOTE Confidence: 0.848489582538605

00:47:28.470 --> 00:47:30.885 How would you view the sequencing and
NOTE Confidence: 0.848489582538605

00:47:30.885 --> 00:47:33.750 where should we position car T cells
NOTE Confidence: 0.848489582538605

00:47:33.750 --> 00:47:35.510 versus the bispecific antibodies?
NOTE Confidence: 0.848489582538605

00:47:35.510 --> 00:47:37.465 Given that the response rates
NOTE Confidence: 0.848489582538605

00:47:37.465 --> 00:47:39.420 are quite significant for both?
NOTE Confidence: 0.825808227062225

00:47:40.640 --> 00:47:43.608 Yeah, I think that's a very good question.
NOTE Confidence: 0.825808227062225

00:47:43.610 --> 00:47:46.770 Very difficult one to answer and also be
NOTE Confidence: 0.825808227062225

00:47:46.770 --> 00:47:49.539 interested to hear no cars take as well.
NOTE Confidence: 0.825808227062225

00:47:49.540 --> 00:47:52.508 You know currently we don't have any trials.
NOTE Confidence: 0.825808227062225

00:47:52.510 --> 00:47:54.440 Obviously comparing head to head

NOTE Confidence: 0.825808227062225
00:47:54.440 --> 00:47:56.775 car T versus the specifics and
NOTE Confidence: 0.825808227062225
00:47:56.775 --> 00:47:59.113 looking at the BI specifics that are
NOTE Confidence: 0.825808227062225
00:47:59.113 --> 00:48:01.420 against BC mayor targeting the CMA.
NOTE Confidence: 0.825808227062225
00:48:01.420 --> 00:48:04.283 They do have somewhat similar response rates
NOTE Confidence: 0.825808227062225
00:48:04.283 --> 00:48:07.600 an it's but I really think how we position
NOTE Confidence: 0.825808227062225
00:48:07.600 --> 00:48:10.767 him is going to come down to one safety.
NOTE Confidence: 0.825808227062225
00:48:10.770 --> 00:48:12.490 What is the cytokine release?
NOTE Confidence: 0.825808227062225
00:48:12.490 --> 00:48:14.245 What is the neurotoxicity in
NOTE Confidence: 0.825808227062225
00:48:14.245 --> 00:48:16.270 these agents and then two is?
NOTE Confidence: 0.825808227062225
00:48:16.270 --> 00:48:18.334 Can we move party to the
NOTE Confidence: 0.825808227062225
00:48:18.334 --> 00:48:19.710 outpatient setting with these?
NOTE Confidence: 0.825808227062225
00:48:19.710 --> 00:48:21.470 Engineer does know for discussed
NOTE Confidence: 0.825808227062225
00:48:21.470 --> 00:48:24.282 bites are a little bit maybe a little
NOTE Confidence: 0.825808227062225
00:48:24.282 --> 00:48:26.244 bit more user friendly I guess.
NOTE Confidence: 0.825808227062225
00:48:26.250 --> 00:48:28.350 Is there off the shelf versus the
NOTE Confidence: 0.825808227062225

00:48:28.350 --> 00:48:30.652 Carty has to be manufactured so also
NOTE Confidence: 0.825808227062225

00:48:30.652 --> 00:48:33.101 keeping in mind it may come down
NOTE Confidence: 0.825808227062225

00:48:33.101 --> 00:48:35.411 to one patient needs therapy now
NOTE Confidence: 0.825808227062225

00:48:35.411 --> 00:48:37.282 device specifics that are targeting
NOTE Confidence: 0.825808227062225

00:48:37.282 --> 00:48:39.774 other things besides BC MA did have
NOTE Confidence: 0.825808227062225

00:48:39.774 --> 00:48:41.800 activity in those patients who had.
NOTE Confidence: 0.825808227062225

00:48:41.800 --> 00:48:43.896 Why are car T so it is feasible
NOTE Confidence: 0.825808227062225

00:48:43.896 --> 00:48:46.157 that you could do party followed by
NOTE Confidence: 0.825808227062225

00:48:46.157 --> 00:48:48.420 a fight with a different targets.
NOTE Confidence: 0.825808227062225

00:48:48.420 --> 00:48:50.852 But again I think we need a lot
NOTE Confidence: 0.825808227062225

00:48:50.852 --> 00:48:52.509 more data know for what
NOTE Confidence: 0.792625725269318

00:48:52.510 --> 00:48:53.455 is your take.
NOTE Confidence: 0.792625725269318

00:48:53.455 --> 00:48:55.030 Yeah I think you're right.
NOTE Confidence: 0.792625725269318

00:48:55.030 --> 00:48:56.610 I think we're still early.
NOTE Confidence: 0.792625725269318

00:48:56.610 --> 00:48:58.305 Unfortunately it's hard to compare
NOTE Confidence: 0.792625725269318

00:48:58.305 --> 00:49:00.334 head to head these studies because

NOTE Confidence: 0.792625725269318

00:49:00.334 --> 00:49:02.280 some of these are off the shelf.

NOTE Confidence: 0.792625725269318

00:49:02.280 --> 00:49:05.430 Some of these need time so it's study to do.

NOTE Confidence: 0.792625725269318

00:49:05.430 --> 00:49:07.815 I think one thing to keep in mind is

NOTE Confidence: 0.792625725269318

00:49:07.815 --> 00:49:10.146 that bites you have frequent dosing,

NOTE Confidence: 0.792625725269318

00:49:10.150 --> 00:49:12.130 whereas Carty is at one time.

NOTE Confidence: 0.792625725269318

00:49:12.130 --> 00:49:13.510 Infusion so that's been

NOTE Confidence: 0.792625725269318

00:49:13.510 --> 00:49:14.545 attractive for patients.

NOTE Confidence: 0.792625725269318

00:49:14.550 --> 00:49:16.365 Also, it's important to remember

NOTE Confidence: 0.792625725269318

00:49:16.365 --> 00:49:18.881 that you know for bites you you

NOTE Confidence: 0.792625725269318

00:49:18.881 --> 00:49:20.777 need a good indulgence T cells.

NOTE Confidence: 0.792625725269318

00:49:20.780 --> 00:49:23.195 So it went in terms of sequencing.

NOTE Confidence: 0.792625725269318

00:49:23.200 --> 00:49:24.440 Someone were to sequence.

NOTE Confidence: 0.792625725269318

00:49:24.440 --> 00:49:26.982 You want to give some time if someone

NOTE Confidence: 0.792625725269318

00:49:26.982 --> 00:49:29.462 gets it Carty and they're getting one for

NOTE Confidence: 0.792625725269318

00:49:29.523 --> 00:49:31.848 depleting therapy in their progressing,

NOTE Confidence: 0.792625725269318

00:49:31.850 --> 00:49:33.770 giving them a bite is not
NOTE Confidence: 0.792625725269318

00:49:33.770 --> 00:49:35.660 going to be very useful.
NOTE Confidence: 0.792625725269318

00:49:35.660 --> 00:49:37.739 So waiting a few months for improvement
NOTE Confidence: 0.792625725269318

00:49:37.739 --> 00:49:39.892 in their in their counsel lymphocyte
NOTE Confidence: 0.792625725269318

00:49:39.892 --> 00:49:42.298 count would be important to remember.
NOTE Confidence: 0.792625725269318

00:49:42.300 --> 00:49:43.770 Although I know these patients
NOTE Confidence: 0.792625725269318

00:49:43.770 --> 00:49:45.860 are very sick and some treatment.
NOTE Confidence: 0.774571120738983

00:49:46.470 --> 00:49:49.375 Thank you Terry and no far another
NOTE Confidence: 0.774571120738983

00:49:49.375 --> 00:49:51.150 question from Doctor Gowda.
NOTE Confidence: 0.774571120738983

00:49:51.150 --> 00:49:53.846 In the with the advent of BCM a
NOTE Confidence: 0.774571120738983

00:49:53.846 --> 00:49:56.250 targeted drug conjugates antibodies.
NOTE Confidence: 0.774571120738983

00:49:56.250 --> 00:50:00.500 How do how do we select again BC MA targeted?
NOTE Confidence: 0.774571120738983

00:50:00.500 --> 00:50:03.116 Whether we propose using an antibiotic
NOTE Confidence: 0.774571120738983

00:50:03.116 --> 00:50:05.599 conjugates or at the CMA cart.
NOTE Confidence: 0.774571120738983

00:50:05.600 --> 00:50:08.150 I think to some of this
NOTE Confidence: 0.774571120738983

00:50:08.150 --> 00:50:09.850 you already alluded to,

NOTE Confidence: 0.774571120738983
00:50:09.850 --> 00:50:11.550 but any further comments?
NOTE Confidence: 0.747536480426788
00:50:16.280 --> 00:50:18.668 I again I think it's hard.
NOTE Confidence: 0.747536480426788
00:50:18.670 --> 00:50:21.058 I think whenever we choose a
NOTE Confidence: 0.747536480426788
00:50:21.058 --> 00:50:22.650 treatment for our patients,
NOTE Confidence: 0.747536480426788
00:50:22.650 --> 00:50:25.387 it's looking at the patient looking the
NOTE Confidence: 0.747536480426788
00:50:25.387 --> 00:50:27.818 disease and looking at the convenience
NOTE Confidence: 0.747536480426788
00:50:27.820 --> 00:50:30.420 and toxicities of the drug and an adjusting
NOTE Confidence: 0.747536480426788
00:50:30.420 --> 00:50:32.998 it to them individual preferences.
NOTE Confidence: 0.747536480426788
00:50:33.000 --> 00:50:34.990 Another question from Doctor Gorshin
NOTE Confidence: 0.747536480426788
00:50:34.990 --> 00:50:36.980 with the updated Griffin data,
NOTE Confidence: 0.747536480426788
00:50:36.980 --> 00:50:39.254 does this impact our decision upfront
NOTE Confidence: 0.747536480426788
00:50:39.254 --> 00:50:41.350 therapy for high risk disease.
NOTE Confidence: 0.747536480426788
00:50:41.350 --> 00:50:42.742 KRD reverses Dara RVD.
NOTE Confidence: 0.747536480426788
00:50:42.742 --> 00:50:45.833 I think KRD still remains a very powerful
NOTE Confidence: 0.747536480426788
00:50:45.833 --> 00:50:48.168 induction therapy with very good.
NOTE Confidence: 0.747536480426788

00:50:48.170 --> 00:50:50.175 Fresh listen with sustain standards
NOTE Confidence: 0.747536480426788

00:50:50.175 --> 00:50:51.779 with continued therapy off.
NOTE Confidence: 0.747536480426788

00:50:51.780 --> 00:50:54.510 Note when you look at the composition
NOTE Confidence: 0.747536480426788

00:50:54.510 --> 00:50:56.589 of patients in the trials,
NOTE Confidence: 0.747536480426788

00:50:56.590 --> 00:50:59.810 the port a trial had about 30% of
NOTE Confidence: 0.747536480426788

00:50:59.810 --> 00:51:02.270 high risk patients that they all
NOTE Confidence: 0.747536480426788

00:51:02.270 --> 00:51:04.209 equally benefited with Dara RVD.
NOTE Confidence: 0.747536480426788

00:51:04.210 --> 00:51:06.616 This is a face to randomization
NOTE Confidence: 0.747536480426788

00:51:06.616 --> 00:51:09.501 and there were 15% of patients who
NOTE Confidence: 0.747536480426788

00:51:09.501 --> 00:51:11.636 harbored high risk cytogenetic profile
NOTE Confidence: 0.747536480426788

00:51:11.636 --> 00:51:14.380 and in their forest plots of data
NOTE Confidence: 0.747536480426788

00:51:14.380 --> 00:51:17.040 which I didn't present in the slides.
NOTE Confidence: 0.747536480426788

00:51:17.040 --> 00:51:19.338 It appeared that as though higher
NOTE Confidence: 0.747536480426788

00:51:19.338 --> 00:51:21.530 risks are genetic profile patients.
NOTE Confidence: 0.747536480426788

00:51:21.530 --> 00:51:24.368 May not have experienced the same
NOTE Confidence: 0.747536480426788

00:51:24.368 --> 00:51:26.882 magnitude of benefit in terms

NOTE Confidence: 0.747536480426788
00:51:26.882 --> 00:51:28.499 of deeper responses,
NOTE Confidence: 0.747536480426788
00:51:28.500 --> 00:51:31.601 so I would say there seem to
NOTE Confidence: 0.747536480426788
00:51:31.601 --> 00:51:34.000 be equally potent regiments.
NOTE Confidence: 0.747536480426788
00:51:34.000 --> 00:51:34.746 My own.
NOTE Confidence: 0.747536480426788
00:51:34.746 --> 00:51:36.984 Practice preference has been KRD for
NOTE Confidence: 0.747536480426788
00:51:36.984 --> 00:51:39.551 high risk patients generally and this
NOTE Confidence: 0.747536480426788
00:51:39.551 --> 00:51:42.790 I hear from some other institutions as well,
NOTE Confidence: 0.747536480426788
00:51:42.790 --> 00:51:45.124 but again practice patterns very in
NOTE Confidence: 0.747536480426788
00:51:45.124 --> 00:51:48.312 more data on the long term follow up
NOTE Confidence: 0.747536480426788
00:51:48.312 --> 00:51:51.046 is needed from the Griffin trial to
NOTE Confidence: 0.747536480426788
00:51:51.046 --> 00:51:53.638 you know where we don't have yet the
NOTE Confidence: 0.747536480426788
00:51:53.640 --> 00:51:55.180 progression free survival benefit.
NOTE Confidence: 0.747536480426788
00:51:55.180 --> 00:51:58.540 Eras for the for the four day trial,
NOTE Confidence: 0.747536480426788
00:51:58.540 --> 00:52:01.078 we have significantly longer follow up,
NOTE Confidence: 0.747536480426788
00:52:01.080 --> 00:52:04.272 so I think both regiments could be
NOTE Confidence: 0.747536480426788

00:52:04.272 --> 00:52:06.600 used interchangeably depending on the
NOTE Confidence: 0.747536480426788

00:52:06.600 --> 00:52:08.805 practice pattern off the institution.
NOTE Confidence: 0.747536480426788

00:52:08.810 --> 00:52:13.300 One question from Doctor Gowda.
NOTE Confidence: 0.747536480426788

00:52:13.300 --> 00:52:15.100 At relapse, for instance,
NOTE Confidence: 0.747536480426788

00:52:15.100 --> 00:52:17.800 if a patient was previously exposed
NOTE Confidence: 0.747536480426788

00:52:17.875 --> 00:52:20.020 to anti BCM, a targeted therapy,
NOTE Confidence: 0.747536480426788

00:52:20.020 --> 00:52:22.540 what is the BCM? A expression?
NOTE Confidence: 0.747536480426788

00:52:22.540 --> 00:52:25.900 Has this been looked at in the literature?
NOTE Confidence: 0.747536480426788

00:52:25.900 --> 00:52:29.260 I would ask either one of the speakers,
NOTE Confidence: 0.747536480426788

00:52:29.260 --> 00:52:31.780 but perhaps more so so far.
NOTE Confidence: 0.80912721157074

00:52:32.420 --> 00:52:34.796 So I know they are looking at it.
NOTE Confidence: 0.80912721157074

00:52:34.800 --> 00:52:37.168 I I don't recall if they published it,
NOTE Confidence: 0.80912721157074

00:52:37.170 --> 00:52:39.011 but there's a lot of and they're
NOTE Confidence: 0.80912721157074

00:52:39.011 --> 00:52:40.739 also looking at Solomon Soluble.
NOTE Confidence: 0.80912721157074

00:52:40.740 --> 00:52:45.572 Be CMA in the blood, but I can't recall.
NOTE Confidence: 0.80912721157074

00:52:45.572 --> 00:52:47.640 What's published? Yeah,

NOTE Confidence: 0.76650208234787

00:52:47.640 --> 00:52:49.595 I don't believe there is

NOTE Confidence: 0.76650208234787

00:52:49.595 --> 00:52:51.550 any published data on this.

NOTE Confidence: 0.76650208234787

00:52:51.550 --> 00:52:52.594 To my knowledge.

NOTE Confidence: 0.76650208234787

00:52:52.594 --> 00:52:54.682 I know each individual company is

NOTE Confidence: 0.76650208234787

00:52:54.682 --> 00:52:56.373 conducting their Olalla Sideclick

NOTE Confidence: 0.76650208234787

00:52:56.373 --> 00:52:57.657 preclinical and correlative

NOTE Confidence: 0.76650208234787

00:52:57.657 --> 00:52:59.369 studies to examine this,

NOTE Confidence: 0.76650208234787

00:52:59.370 --> 00:53:02.810 but not entirely clear yet.

NOTE Confidence: 0.858881711959839

00:53:02.810 --> 00:53:05.108 So with that, I think we're

NOTE Confidence: 0.858881711959839

00:53:05.110 --> 00:53:07.408 a four minutes after the hour.

NOTE Confidence: 0.858881711959839

00:53:07.410 --> 00:53:09.315 Thank you for the excellent

NOTE Confidence: 0.858881711959839

00:53:09.315 --> 00:53:10.849 presentations. All of you.

NOTE Confidence: 0.858881711959839

00:53:10.849 --> 00:53:12.764 I really appreciate everybody joining.

NOTE Confidence: 0.858881711959839

00:53:12.770 --> 00:53:14.900 I hope this was an informative

NOTE Confidence: 0.858881711959839

00:53:14.900 --> 00:53:17.464 session and hope to see you all

NOTE Confidence: 0.858881711959839

00:53:17.464 --> 00:53:19.239 for the subsequent sessions of

NOTE Confidence: 0.858881711959839

00:53:19.239 --> 00:53:21.786 the ash highlights. Thank you.

NOTE Confidence: 0.858881711959839

00:53:21.786 --> 00:53:24.226 Have a great day everybody.

NOTE Confidence: 0.858881711959839

00:53:24.230 --> 00:53:26.696 Thank you for organizing doctors item.